Topic: Electrophysiology

Abstract

Time series proteome profile analysis reveals a protective role of citrate synthase in angiotensin II-induced atrial fibrillation.

Teng F, Han X, Yu P, Li PB, Li HH, Zhang YL
Background
Angiotensin (Ang) II and elevated blood pressure are considered to be the main risk factors for atrial fibrillation. However, the proteome profiles and key mediators/signaling pathways involved in the development of Ang II-induced atrial fibrillation remain unclear.
Methods
Male wild-type C57BL/6 mice (10-week old) were infused with Ang II (2000 ng/kg per min) for 1, 2, or 3 weeks, respectively. Time series proteome profiling of atrial tissues was performed using isobaric tags for relative and absolute quantitation and liquid chromatography coupled with tandem mass spectrometry.
Results
We identified a total of 1566 differentially expressed proteins (DEPs) in the atrial tissues at weeks 1, 2, and 3 after Ang II infusion. These DEPs were predominantly involved in mitochondrial oxidation-reduction and tricarboxylic acid cycle in Ang II-infused atria. Moreover, coexpression network analysis revealed that citrate synthase, a rate-limiting enzyme in the tricarboxylic acid cycle, was localized at the center of the mitochondrial oxidation-reduction process, and its expression was significantly downreguated in Ang II-infused atria at different time points. Cardiomyocyte-specific overexpresion of citrate synthase markedly reduced atrial fibrillation susceptibility and atrial remodeling in mice. These beneficial effects were associated with increased ATP production and mitochondrial oxidative phosphorylation system complexes I-V expression and inhibition of oxidative stress.
Conclusion
The current study defines the dynamic changes of the DEPs involved in Ang II-induced atrial fibrillation, and identifies that citrate synthase plays a protective role in regulating atrial fibrillation development, and increased citrate synthase expression may represent a potential therapeutic option for atrial fibrillation treatment.

Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.

J Hypertens: 31 Mar 2022; 40:765-775
Teng F, Han X, Yu P, Li PB, Li HH, Zhang YL
J Hypertens: 31 Mar 2022; 40:765-775 | PMID: 35013064
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Renal decline in patients with non-valvular atrial fibrillation treated with rivaroxaban or warfarin: A population-based study from the United Kingdom.

González Pérez A, Balabanova Y, Sáez ME, Brobert G, García Rodríguez LA
Background
Reports suggest that renal decline is greater among patients with non-valvular atrial fibrillation (NVAF) treated chronically with warfarin vs. some non-vitamin K antagonist oral anticoagulants.
Methods and results
Using primary care electronic health records from the United Kingdom we followed adults with NVAF and who started rivaroxaban (20 mg/day, N = 5338) or warfarin (N = 6314), excluding those with estimated glomerular filtration rate (eGFR) <50 ml/min/1.73m2, end-stage renal disease (ESRD) or no eGFR or serum creatinine (SCr) values recorded in the previous year. Outcomes were: doubling SCr levels, ≥30% decline in eGFR and progression to ESRD. We calculated adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for each outcome. Average eGFR slope was estimated using mixed model regression. After a mean follow-up 2.5 years, the number of incident cases of adverse renal events within the two cohorts was: doubling SCr (n = 322), ≥30% decline in eGFR (n = 1179), and progression to ESRD (n = 22). Adjusted HRs (95% CIs) for the renal outcomes among rivaroxaban vs. warfarin users were: doubling SCr, 0.63 (0.49-0.81); ≥30% decline in eGFR, 0.76 (0.67-0.86); ESRD, 0.77 (0.29-2.04). Similar results were observed among patients with diabetes or heart failure. Estimated mean decline in renal function over the study period was 2.03 ml/min/1.73 m2/year among warfarin users and 1.65 ml/min/1.73 m2/year among rivaroxaban users (p = 0.03).
Conclusions
We found clear evidence that patients with NVAF, preserved renal function at baseline and treated with rivaroxaban had a markedly reduced risk and rate of renal decline compared with those treated with warfarin.

Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.

Int J Cardiol: 31 Mar 2022; 352:165-171
González Pérez A, Balabanova Y, Sáez ME, Brobert G, García Rodríguez LA
Int J Cardiol: 31 Mar 2022; 352:165-171 | PMID: 35122912
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

An unprecedented cause of cardiac resynchronization with defibrillator (CRT-D) malfunction \"A beheaded generator assembly\".

Prasitlumkum N, Ding K, Doyle K, Pai RG, Lo R
Cardiac resynchronization with defibrillator (CRT-D) malfunction can be due to various reasons, including wire injury, insulation break, battery problems, or patient factors. Undesired outcomes can be dramatically elevated in those settings, prompting early detection and proper troubleshooting. To diagnose, clinical correlation and device interrogation are vital. However, it is not uncommon to find general troubleshooting options insufficient, as highlighted in this case report. Here, we presented an unusual \"head assembly separation,\" as the main reason for abnormal device parameters.

© 2022 Wiley Periodicals LLC.

J Cardiovasc Electrophysiol: 31 Mar 2022; 33:769-772
Prasitlumkum N, Ding K, Doyle K, Pai RG, Lo R
J Cardiovasc Electrophysiol: 31 Mar 2022; 33:769-772 | PMID: 35118754
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Trends in the pharmacological management of atrial fibrillation in UK general practice 2008-2018.

Phillips K, Subramanian A, Thomas GN, Khan N, ... Fabritz L, Adderley NJ
Objective
The pharmacological management of atrial fibrillation (AF) comprises anticoagulation, for stroke prophylaxis, and rate or rhythm control drugs to alleviate symptoms and prevent heart failure. The aim of this study was to investigate trends in the proportion of patients with AF prescribed pharmacological therapies in the UK between 2008 and 2018.
Methods
Eleven sequential cross-sectional analyses were performed yearly from 2008 to 2018. Data were derived from an anonymised UK primary care database. Outcomes were the proportion of patients with AF prescribed anticoagulants, rhythm and rate control drugs in the whole cohort, those at high risk of stroke and those with coexisting heart failure.
Results
Between 2008 and 2018, the proportion of patients prescribed anticoagulants increased from 45.3% (95% CI 45.0% to 45.7%) to 71.1% (95% CI 70.7% to 71.5%) driven by increased prescription of non-vitamin K antagonist anticoagulants. The proportion of patients prescribed rate control drugs remained constant between 2008 and 2018 (69.3% (95% CI 68.9% to 69.6%) to 71.6% (95% CI 71.2% to 71.9%)). The proportion of patients prescribed rhythm control therapy by general practitioners (GPs) decreased from 9.5% (95% CI 9.3% to 9.7%) to 5.4% (95% CI 5.2% to 5.6%).
Conclusions
There has been an increase in the proportion of patients with AF appropriately prescribed anticoagulants following National Institute for Health and Care Excellence and European Society of Cardiology guidelines, which correlates with improvements in mortality and stroke outcomes. Beta-blockers appear increasingly favoured over digoxin for rate control. There has been a steady decline in GP prescribing rates for rhythm control drugs, possibly related to concerns over efficacy and safety and increased availability of AF ablation.

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Heart: 30 Mar 2022; 108:517-522
Phillips K, Subramanian A, Thomas GN, Khan N, ... Fabritz L, Adderley NJ
Heart: 30 Mar 2022; 108:517-522 | PMID: 34226195
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Utility of the CHA2DS2-VASc score for predicting ischaemic stroke in patients with or without atrial fibrillation: a systematic review and meta-analysis.

Siddiqi TJ, Usman MS, Shahid I, Ahmed J, ... Rihal CS, Alkhouli M
Aims
Anticoagulants are the mainstay treatment for stroke prevention in patients with non-valvular atrial fibrillation (NVAF), and the CHA2DS2-VASc score is widely used to guide anticoagulation therapy in this cohort. However, utility of CHA2DS2-VASc in NVAF patients is debated, primarily because it is a vascular scoring system, which does not incorporate atrial fibrillation related parameters. Therefore, we conducted a meta-analysis to estimate the discrimination ability of CHA2DS2-VASc in predicting ischaemic stroke overall, and in subgroups of patients with or without NVAF.
Methods and results
PubMed and Embase databases were searched till June 2020 for published articles that assessed the discrimination ability of CHA2DS2-VASc, as measured by C-statistics, during mid-term (2-5 years) and long-term (>5 years) follow-up. Summary estimates were reported as random effects C-statistics with 95% confidence intervals (CIs). Seventeen articles were included in the analysis. Nine studies (n = 453 747 patients) reported the discrimination ability of CHA2DS2-VASc in NVAF patients, and 10 studies (n = 138 262 patients) in patients without NVAF. During mid-term follow-up, CHA2DS2-VASc predicted stroke with modest discrimination in the overall cohort [0.67 (0.65-0.69)], with similar discrimination ability in patients with NVAF [0.65 (0.63-0.68)] and in those without NVAF [0.69 (0.68-0.71)] (P-interaction = 0.08). Similarly, at long-term follow-up, CHA2DS2-VASc had modest discrimination [0.66 (0.63-0.69)], which was consistent among patients with NVAF [0.63 (0.54-0.71)] and those without NVAF [0.67 (0.64-0.70)] (P-interaction = 0.39).
Conclusion
This meta-analysis suggests that the discrimination power of the CHA2DS2-VASc score in predicting ischaemic stroke is modest, and is similar in the presence or absence of NVAF. More accurate stroke prediction models are thus needed for the NVAF population.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

Eur J Prev Cardiol: 30 Mar 2022; 29:625-631
Siddiqi TJ, Usman MS, Shahid I, Ahmed J, ... Rihal CS, Alkhouli M
Eur J Prev Cardiol: 30 Mar 2022; 29:625-631 | PMID: 33693717
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

The role of phosphorylation in atrial fibrillation: a focus on mass spectrometry approaches.

Safabakhsh S, Panwar P, Barichello S, Sangha SS, ... Petegem FV, Laksman Z
Atrial fibrillation (AF) is the most common arrhythmia worldwide. It is associated with significant increases in morbidity in the form of stroke and heart failure, and a doubling in all-cause mortality. The pathophysiology of AF is incompletely understood, and this has contributed to a lack of effective treatments and disease-modifying therapies. An important cellular process that may explain how risk factors give rise to AF includes post-translational modification of proteins. As the most commonly occurring post-translational modification, protein phosphorylation is especially relevant. Although many methods exist for studying protein phosphorylation, a common and highly resolute technique is mass spectrometry (MS). This review will discuss recent evidence surrounding the role of protein phosphorylation in the pathogenesis of AF. MS-based technology to study phosphorylation and uses of MS in other areas of medicine such as oncology will also be presented. Based on these data, future goals and experiments will be outlined that utilize MS technology to better understand the role of phosphorylation in AF and elucidate its role in AF pathophysiology. This may ultimately allow for the development of more effective AF therapies.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

Cardiovasc Res: 25 Mar 2022; 118:1205-1217
Safabakhsh S, Panwar P, Barichello S, Sangha SS, ... Petegem FV, Laksman Z
Cardiovasc Res: 25 Mar 2022; 118:1205-1217 | PMID: 33744917
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Influence of sex on intracellular calcium homoeostasis in patients with atrial fibrillation.

Herraiz-Martínez A, Tarifa C, Jiménez-Sábado V, Llach A, ... Cinca J, Hove-Madsen L
Aims
Atrial fibrillation (AF) has been associated with intracellular calcium disturbances in human atrial myocytes, but little is known about the potential influence of sex and we here aimed to address this issue.
Methods and results
Alterations in calcium regulatory mechanisms were assessed in human atrial myocytes from patients without AF or with long-standing persistent or permanent AF. Patch-clamp measurements revealed that L-type calcium current (ICa) density was significantly smaller in males with than without AF (-1.15 ± 0.37 vs. -2.06 ± 0.29 pA/pF) but not in females with AF (-1.88 ± 0.40 vs. -2.21 ± 0.0.30 pA/pF). In contrast, transient inward currents (ITi) were more frequent in females with than without AF (1.92 ± 0.36 vs. 1.10 ± 0.19 events/min) but not in males with AF. Moreover, confocal calcium imaging showed that females with AF had more calcium spark sites than those without AF (9.8 ± 1.8 vs. 2.2 ± 1.9 sites/µm2) and sparks were wider (3.0 ± 0.3 vs. 2.2 ± 0.3 µm) and lasted longer (79 ± 6 vs. 55 ± 8 ms), favouring their fusion into calcium waves that triggers ITIs and afterdepolarizations. This was linked to higher ryanodine receptor phosphorylation at s2808 in women with AF, and inhibition of adenosine A2A or beta-adrenergic receptors that modulate s2808 phosphorylation was able to reduce the higher incidence of ITI in women with AF.
Conclusion
Perturbations of the calcium homoeostasis in AF is sex-dependent, concurring with increased spontaneous SR calcium release-induced electrical activity in women but not in men, and with diminished ICa density in men only.

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

Cardiovasc Res: 16 Mar 2022; 118:1033-1045
Herraiz-Martínez A, Tarifa C, Jiménez-Sábado V, Llach A, ... Cinca J, Hove-Madsen L
Cardiovasc Res: 16 Mar 2022; 118:1033-1045 | PMID: 33788918
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry.

Lip GYH, Kotalczyk A, Teutsch C, Diener HC, ... Huisman MV, GLORIA-AF Investigators
Background:
and purpose
Prospectively collected data comparing the safety and effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective was to directly compare the effectiveness and safety of NOACs in patients with newly diagnosed atrial fibrillation (AF).
Methods
In GLORIA-AF, a large, prospective, global registry program, consecutive patients with newly diagnosed AF were followed for 3 years. The comparative analyses for (1) dabigatran vs rivaroxaban or apixaban and (2) rivaroxaban vs apixaban were performed on propensity score (PS)-matched patient sets. Proportional hazards regression was used to estimate hazard ratios (HRs) for outcomes of interest.
Results
The GLORIA-AF Phase III registry enrolled 21,300 patients between January 2014 and December 2016. Of these, 3839 were prescribed dabigatran, 4015 rivaroxaban and 4505 apixaban, with median ages of 71.0, 71.0, and 73.0 years, respectively. In the PS-matched set, the adjusted HRs and 95% confidence intervals (CIs) for dabigatran vs rivaroxaban were, for stroke: 1.27 (0.79-2.03), major bleeding 0.59 (0.40-0.88), myocardial infarction 0.68 (0.40-1.16), and all-cause death 0.86 (0.67-1.10). For the comparison of dabigatran vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 1.16 (0.76-1.78), myocardial infarction 0.84 (0.48-1.46), major bleeding 0.98 (0.63-1.52) and all-cause death 1.01 (0.79-1.29). For the comparison of rivaroxaban vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 0.78 (0.52-1.19), myocardial infarction 0.96 (0.63-1.45), major bleeding 1.54 (1.14-2.08), and all-cause death 0.97 (0.80-1.19).
Conclusions
Patients treated with dabigatran had a 41% lower risk of major bleeding compared with rivaroxaban, but similar risks of stroke, MI, and death. Relative to apixaban, patients treated with dabigatran had similar risks of stroke, major bleeding, MI, and death. Rivaroxaban relative to apixaban had increased risk for major bleeding, but similar risks for stroke, MI, and death.
Registration
URL: https://www.
Clinicaltrials
gov . Unique identifiers: NCT01468701, NCT01671007. Date of registration: September 2013.

© 2022. The Author(s).

Clin Res Cardiol: 15 Mar 2022; epub ahead of print
Lip GYH, Kotalczyk A, Teutsch C, Diener HC, ... Huisman MV, GLORIA-AF Investigators
Clin Res Cardiol: 15 Mar 2022; epub ahead of print | PMID: 35294625
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry.

Huisman MV, Teutsch C, Lu S, Diener HC, ... Lip GYH, GLORIA-AF Investigators
Background
Prospectively collected, routine clinical practice-based data on antithrombotic therapy in non-valvular atrial fibrillation (AF) patients are important for assessing real-world comparative outcomes. The objective was to compare the safety and effectiveness of dabigatran versus vitamin K antagonists (VKAs) in patients with newly diagnosed AF.
Methods and results
GLORIA-AF is a large, prospective, global registry program. Consecutive patients with newly diagnosed AF and CHA2DS2-VASc scores ≥ 1 were included and followed for 3 years. To control for differences in patient characteristics, the comparative analysis for dabigatran versus VKA was performed on a propensity score (PS)-matched patient set. Missing data were multiply imputed. Proportional-hazards regression was used to estimate hazard ratios (HRs) for outcomes of interest. Between 2014 and 2016, 21,300 eligible patients were included worldwide: 3839 patients were prescribed dabigatran and 4836 VKA with a median age of 71.0 and 72.0 years, respectively; > 85% in each group had a CHA2DS2-VASc-score ≥ 2. The PS-matched comparative analysis for dabigatran and VKA included on average 3326 pairs of matched initiators. For dabigatran versus VKAs, adjusted HRs (95% confidence intervals) were: stroke 0.89 (0.59-1.34), major bleeding 0.61 (0.42-0.88), all-cause death 0.78 (0.63-0.97), and myocardial infarction 0.89 (0.53-1.48). Further analyses stratified by PS and region provided similar results.
Conclusions
Dabigatran was associated with a 39% reduced risk of major bleeding and 22% reduced risk for all-cause death compared with VKA. Stroke and myocardial infarction risks were similar, confirming a more favorable benefit-risk profile for dabigatran compared with VKA in clinical practice. Clinical trial registration https://www.
Clinicaltrials
gov . NCT01468701, NCT01671007.

© 2022. The Author(s).

Clin Res Cardiol: 15 Mar 2022; epub ahead of print
Huisman MV, Teutsch C, Lu S, Diener HC, ... Lip GYH, GLORIA-AF Investigators
Clin Res Cardiol: 15 Mar 2022; epub ahead of print | PMID: 35294623
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Actual management costs of patients with non-valvular atrial fibrillation treated with percutaneous left atrial appendage closure or oral anticoagulation.

D\'Ancona G, Arslan F, Safak E, Weber D, Al Ammareen R, Ince H
Aims
Comparing actual management costs in patients with non-valvular atrial fibrillation (AF) treated with percutaneous left atrial appendage closure (LAAC) or OAC only.
Methods and results
Patients undergoing percutaneous LAAC and AF patients treated with OAC only were matched for gender, age, and diagnosis related groups (DRG) clinical complexity level (CCL). Costs for cardiovascular outpatient clinic visits and hospitalizations were derived from the actual reimbursement records. Between 1/2012 and 12/2016, 8478 patients were referred: 7801 (92%) managed with OAC and 677 (8%) with percutaneous LAAC. Matching resulted in 558 patients (279 per group) for final analysis. Age was 74.9 ± 7.5 years, 244 were female (43.7%), and DRG CCL was 1.8 ± 1.1. Annualized management cost before percutaneous LAAC was € 3110 (IQR: € 1281-8127). After 4.5 ± 1.4 years follow-up, annualized management cost was € 1297 (IQR: € 607-2735) in OAC patients and € 1013 (IQR: € 0-4770) in patients after percutaneous LAAC (p = 0.003). Percutaneous LAAC was the strongest independent determinant to reduce follow-up costs (B = -0.8; CI: -1.09 ̶̶̶̶̶ -0.6; p < 0.0001). Estimated 3-year survival was 92% in percutaneous LAAC and 90% in OAC patients (p = 0.7).
Conclusion
Percutaneous LAAC significantly reduces management costs. Management costs are significantly higher for patients treated with only OAC compared to patients after percutaneous LAAC. In spite of their complex comorbid profile, percutaneous LAAC patients show a follow-up survival rate similar to patients solely treated with OAC. Future studies are necessary to investigate the potential net economic and clinical benefit of percutaneous LAAC in patients treated with OAC only.

Copyright © 2021 Elsevier B.V. All rights reserved.

Int J Cardiol: 14 Mar 2022; 351:61-64
D'Ancona G, Arslan F, Safak E, Weber D, Al Ammareen R, Ince H
Int J Cardiol: 14 Mar 2022; 351:61-64 | PMID: 34929249
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

The risk and timing of acute ischemic stroke after electrical cardioversion for atrial fibrillation in Taiwan: A nationwide population-based cohort study.

Huang CK, Wang JC, Chung CH, Chen SJ, Liao WI, Chien WC
Background
There is a positive association between electrical cardioversion (ECV) and acute ischemic stroke (AIS). Although 4 weeks of anticoagulation therapy after ECV in atrial fibrillation (AF) patients is generally suggested by current guidelines to reduce the risk of AIS, limited studies have been conducted in Asian populations to determine the risk and timing of AIS after ECV for AF in recent years. Therefore, we aim to use the National Health Insurance Research Database (NHIRD) in Taiwan to determine the risk and timing of AIS after ECV for AF.
Methods
The data analyzed in this nationwide population-based retrospective cohort study were obtained from the NHIRD in Taiwan. The outcome in this study was the cumulative incidence of AIS in patients with AF during 7-day and 30-day follow-up periods after the patients underwent ECV.
Results
Our analysis included 39,697 patients with AF, of whom 5723 received ECV and 5723 were propensity score-matched controls. Compared to the controls, patients who received ECV exhibited a significantly increased incidence of 7-day AIS development (adjusted hazard ratio [HR] = 1.524, p = 0.003). In contrast, the incidence of 30-day AIS development showed no significant increase (adjusted HR = 1.301, p = 0.426).
Conclusions
AF patients who underwent ECV had a higher incidence of 7-day AIS development but not 30-day AIS development. Considering the timing of AIS development after ECV in AF patients, the optimal duration of antithrombotic therapy after ECV deserves further investigation.

Copyright © 2021 Elsevier B.V. All rights reserved.

Int J Cardiol: 14 Mar 2022; 351:55-60
Huang CK, Wang JC, Chung CH, Chen SJ, Liao WI, Chien WC
Int J Cardiol: 14 Mar 2022; 351:55-60 | PMID: 34954280
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Investigating the association between P wave duration and atrial fibrillation recurrence after radiofrequency ablation in early persistent atrial fibrillation patients.

Miao Y, Xu M, Yang L, Zhang C, Liu H, Shao X
Background
In the present study, we aimed to explore the association between P wave duration, as the measured time from the start point of the P wave to the end point, and atrial fibrillation recurrence after transcatheter radiofrequency ablation in patients with early persistent atrial fibrillation.
Methods
Patients with early persistent atrial fibrillation who underwent the first radiofrequency ablation procedure were retrospectively analyzed. The electrocardiographic, echocardiographic and clinical data of the enrolled patients before and after operation were collected and recorded. After adjusting confounding factors and performing stratified analysis, the association between the P wave duration and the atrial fibrillation recurrence of patients with early persistent atrial fibrillation after radiofrequency ablation was explored.
Results
The proportions of atrial fibrillation recurrence of the low, medium, and high P wave duration groups were 6.4%, 19.7%, and 47.0%, respectively. After potential confounding factors were adjusted, the risk of atrial fibrillation recurrence gradually increased with the increase of P wave duration (odds ratio: 1.093, 95% confidence interval: 1.063-1.124, p < 0.001). This trend was statistically significant (odds ratio: 1.099, 95% confidence interval: 1.052-1.149, p < 0.001), especially in comparison of high vs. low (odds ratio: 16.99, 95% confidence interval: 4.75-60.78, p < 0.001). Curve fitting showed that there was a linear and positive association between the P wave duration and the risk of atrial fibrillation recurrence. This association was consistent in different subgroups based on gender, drinking, history of smoking, hypertension, diabetes mellitus, peripheral artery disease, stroke or transient ischemia attack, hyperlipidemia, heart failure, and heart rate, suggesting that there was no significant interaction between different grouping parameters and the association (p for interaction range = 0.217-0.965).
Conclusions
In patients with early persistent atrial fibrillation who underwent radiofrequency ablation procedure for the first time and converted to sinus rhythm, the P wave duration within 72 h after the procedure was independently associated with the risk of atrial fibrillation recurrence, and such association was linear and positive.

Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Int J Cardiol: 14 Mar 2022; 351:48-54
Miao Y, Xu M, Yang L, Zhang C, Liu H, Shao X
Int J Cardiol: 14 Mar 2022; 351:48-54 | PMID: 34954277
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Incidence and Predictors of Bleeding in Patients With Cancer and Atrial Fibrillation.

Raposeiras Roubín S, Abu Assi E, Muñoz Pousa I, Domínguez Erquicia P, ... Gonzalez Bermudez I, Íñiguez Romo A
Despite patients with cancer having a higher incidence of atrial fibrillation (AF), little is known about the predictors of outcomes in this population. This study aimed to assess the incidence and predictors of bleeding in patients with AF and cancer. The study population comprised 16,056 patients from a Spanish health area diagnosed with AF between 2014 and 2018 (1,137 with cancer). Competing risk analysis were used to evaluate the association of cancer and bleeding. Discrimination and calibration of bleeding risk scores were assessed by the concordance statistic and the Brier score, respectively. During a median follow-up of 4.9 years, the incidence of bleeding in patients with cancer was 13.2 per 100 patients/year. After multivariate adjustment, a significant association between cancer and bleeding was detected (subdistribution hazard ratio [sHR] 1.18, 95% CI 1.07 to 1.30, p = 0.001), specifically in patients with active cancer or previous radiotherapy. Early age, male gender, diabetes, and anticoagulation were independent predictors of bleeding. However, only anticoagulation with vitamin K antagonist (sHR 1.36, 95% CI 1.03 to 1.78, p = 0.026), not with direct oral anticoagulants (sHR 1.25, 95% CI 0.84 to 1.85, p = 0.270), was associated with bleeding. Discrimination and calibration of Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, and Drugs/alcohol concomitantly (HAS-BLED), AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA), and Hepatic or renal disease, Ethanol abuse, Malignancy, Older (age ≥75 years), Reduced platelet count or function, Rebleeding risk, Hypertension, Anaemia, Genetic factors, Excessive fall risk and Stroke (HEMORR2HAGES) scores were poor in patients with cancer (concordance statistic <0.6 and Brier score >0.1). In summary, cancer was associated with an increased risk of bleeding in patients with AF. The predictive ability of bleeding risk scores was poor in this population. Anticoagulation with vitamin K antagonist but not with direct oral anticoagulants, was an independent predictor of bleeding in patients with cancer.

Copyright © 2021 Elsevier Inc. All rights reserved.

Am J Cardiol: 14 Mar 2022; 167:139-146
Raposeiras Roubín S, Abu Assi E, Muñoz Pousa I, Domínguez Erquicia P, ... Gonzalez Bermudez I, Íñiguez Romo A
Am J Cardiol: 14 Mar 2022; 167:139-146 | PMID: 35027138
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Restoring Sinus Rhythm Reverses Cardiac Remodeling and Reduces Valvular Regurgitation in Patients With Atrial Fibrillation.

Soulat-Dufour L, Lang S, Addetia K, Ederhy S, ... Lang RM, Cohen A
Background
Cardiac chamber remodeling in atrial fibrillation (AF) reflects the progression of cardiac rhythm and may affect functional regurgitation.
Objectives
The purpose of this study was to explore the 3-dimensional echocardiographic variables of cardiac cavity remodeling and the impact on functional regurgitation in patients with AF with/without sinus rhythm restoration at 12 months.
Methods
A total of 117 consecutive patients hospitalized for AF were examined using serial 3-dimensional transthoracic echocardiography at admission, at 6 months, and at 12 months (337 examinations).
Results
During follow-up, 47 patients with active restoration of sinus rhythm (SR) (through cardioversion and/or ablation) had a decrease in all atrial indexed volumes (Vi), end-systolic (ES) right ventricular (RV) Vi, an increase in end-diastolic (ED) left ventricular Vi, and an improvement in 4-chambers function (P < 0.05). Patients with absence/failure of restoration of SR (n = 39) had an increase in ED left atrial Vi and ED/ES RV Vi without modification of 4-chambers function, except for a decrease in left atrial emptying fraction (P < 0.05). Patients with spontaneous restoration of SR (n = 31) had no changes in Vi or function. The authors found an improvement vs baseline in severity of functional regurgitation in patients with active restoration of SR (tricuspid and mitral regurgitation) and in spontaneous restoration of SR (tricuspid regurgitation) (P < 0.05). In multivariable analysis, right atrial and/or left atrial reverse remodeling exclusively correlated with intervention (cardioversion and/or ablation) during 12-month follow-up.
Conclusions
Management of AF should focus on restoration of SR to induce anatomical (all atrial Vi, ES RV Vi) and/or functional (4 chambers) cardiac cavity reverse remodeling and reduce severity of functional regurgitation. (Thromboembolic and Bleeding Risk Stratification in Patients With Non-valvular Atrial Fibrillation [FASTRHAC]; NCT02741349).

Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

J Am Coll Cardiol: 14 Mar 2022; 79:951-961
Soulat-Dufour L, Lang S, Addetia K, Ederhy S, ... Lang RM, Cohen A
J Am Coll Cardiol: 14 Mar 2022; 79:951-961 | PMID: 35272799
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Dronedarone for the Treatment of Atrial Fibrillation with Concomitant Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Post-Hoc Analysis of the ATHENA Trial.

Vaduganathan M, Piccini JP, Camm AJ, Crijns HJGM, ... Wieloch M, Hohnloser SH
Aims
Limited therapeutic options are available for the management of atrial fibrillation/flutter (AF/AFL) with concomitant heart failure with preserved and mildly reduced ejection fraction. (HFpEF and HFmrEF). Dronedarone reduces the risk of cardiovascular events in patients with AF, but sparse data are available examining its role in patients with AF complicated by HFpEF and HFmrEF.
Methods and results
ATHENA was an international, multicenter trial that randomized 4,628 patients with paroxysmal or persistent AF/AFL and cardiovascular risk factors to dronedarone 400 mg twice daily versus placebo. We evaluated patients with 1) symptomatic HFpEF and HFmrEF (defined as LVEF>40%, evidence of structural heart disease, and New York Heart Association class II/III or diuretic use), 2) HF with reduced ejection fraction (HFrEF) or left ventricular dysfunction (LVEF≤40%), and 3) those without HF. We assessed effects of dronedarone vs placebo on death or cardiovascular hospitalization (primary endpoint), other key efficacy endpoints, and safety. Overall, 534 (12%) had HFpEF or HFmrEF, 422 (9%) had HFrEF or LV dysfunction, and 3,672 (79%) did not have HF. Patients with HFpEF and HFmrEF had a mean age of 73±9 years, 37% were women, and had a mean LVEF of 57±9%. Over 21±5 months mean follow-up, dronedarone consistently reduced risk of death or cardiovascular hospitalization (hazard ratio 0.76; 95% confidence interval 0.69-0.84) without heterogeneity based on HF status (Pinteraction >0.10). This risk reduction in the primary endpoint was consistent across the range of LVEF (as a continuous function) in HF without heterogeneity (Pinteraction =0.71). Rates of death, cardiovascular hospitalization, and HF hospitalization each directionally favored dronedarone vs. placebo in HFpEF and HFmrEF, but these treatment effects were not statistically significant.
Conclusions
Dronedarone is associated with reduced cardiovascular events in patients with paroxysmal or persistent AF/AFL and HF across the spectrum of LVEF, including among those with HFpEF and HFmrEF. These data support a rationale for a future dedicated and powered clinical trial to affirm the net clinical benefit of dronedarone in this population.

This article is protected by copyright. All rights reserved.

Eur J Heart Fail: 14 Mar 2022; epub ahead of print
Vaduganathan M, Piccini JP, Camm AJ, Crijns HJGM, ... Wieloch M, Hohnloser SH
Eur J Heart Fail: 14 Mar 2022; epub ahead of print | PMID: 35293087
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

How should I treat patients with subclinical atrial fibrillation and atrial high-rate episodes? Current evidence and clinical importance.

Kreimer F, Mügge A, Gotzmann M
Long-term and continuous ECG monitoring using cardiac implantable electronic devices and insertable cardiac monitors has improved the capability of detecting subclinical atrial fibrillation (AF) and atrial high-rate episodes. Previous studies demonstrated a high prevalence (more than 20%) in patients with cardiac implantable electronic devices or insertable cardiac monitors. Subclinical AF and atrial high-rate episodes are often suspected as the cause of prior or potential future ischemic stroke. However, the clinical significance is still uncertain, and the evidence is limited. This review aims to present and discuss the current evidence on the clinical impact of subclinical AF and atrial high-rate episodes. It focuses particularly on the association between the duration of the episodes and major clinical outcomes like thromboembolic events. As subclinical AF and atrial high-rate episodes are presumed to be associated with ischemic strokes, detection will be particularly important in patients with cryptogenic stroke and in high-risk patients for thromboembolism. In this context, it is also interesting whether there is a temporal relationship between the detection of subclinical AF and atrial high-rate episodes and the occurrence of thromboembolic events. In addition, the review will examine the question whether there is a need for a therapy with oral anticoagulation.

© 2022. The Author(s).

Clin Res Cardiol: 14 Mar 2022; epub ahead of print
Kreimer F, Mügge A, Gotzmann M
Clin Res Cardiol: 14 Mar 2022; epub ahead of print | PMID: 35292844
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation.

Papazoglou AS, Kartas A, Moysidis DV, Tsagkaris C, ... Papadakis M, Giannakoulas G
Atrial fibrillation (AF) and diabetes mellitus (DM) constitute two major closely inter-related chronic cardiovascular disorders whose concurrent prevalence rates are steadily increasing. Although, the pathogenic mechanisms behind the AF and DM comorbidity are still vague, it is now clear that DM precipitates AF occurrence. DM also affects the clinical course of established AF; it is associated with significant increase in the incidence of stroke, AF recurrence, and cardiovascular mortality. The impact of DM on AF management and prognosis has been adequately investigated. However, evidence on the relative impact of glycemic control using glycated hemoglobin levels is scarce. This review assesses up-to-date literature on the association between DM and AF. It also highlights the usefulness of glycated hemoglobin measurement for the prediction of AF and AF-related adverse events. Additionally, this review evaluates current anti-hyperglycemic treatment in the context of AF, and discusses AF-related decision-making in comorbid DM. Finally, it quotes significant remaining questions and sets some future strategies with the potential to effectively deal with this prevalent comorbidity.

© 2022. The Author(s).

Cardiovasc Diabetol: 13 Mar 2022; 21:39
Papazoglou AS, Kartas A, Moysidis DV, Tsagkaris C, ... Papadakis M, Giannakoulas G
Cardiovasc Diabetol: 13 Mar 2022; 21:39 | PMID: 35287684
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Epicardial fat and atrial fibrillation: the perils of atrial failure.

Poggi AL, Gaborit B, Schindler TH, Liberale L, Montecucco F, Carbone F
Obesity is a heterogeneous condition, characterized by different phenotypes and for which the classical assessment with body mass index may underestimate the real impact on cardiovascular (CV) disease burden. An epidemiological link between obesity and atrial fibrillation (AF) has been clearly demonstrated and becomes even more tight when ectopic (i.e. epicardial) fat deposition is considered. Due to anatomical and functional features, a tight paracrine cross-talk exists between epicardial adipose tissue (EAT) and myocardium, including the left atrium (LA). Alongside-and even without-mechanical atrial stretch, the dysfunctional EAT may determine a pro-inflammatory environment in the surrounding myocardial tissue. This evidence has provided a new intriguing pathophysiological link with AF, which in turn is no longer considered a single entity but rather the final stage of atrial remodelling. This maladaptive process would indeed include structural, electric, and autonomic derangement that ultimately leads to overt disease. Here, we update how dysfunctional EAT would orchestrate LA remodelling. Maladaptive changes sustained by dysfunctional EAT are driven by a pro-inflammatory and pro-fibrotic secretome that alters the sinoatrial microenvironment. Structural (e.g. fibro-fatty infiltration) and cellular (e.g. mitochondrial uncoupling, sarcoplasmic reticulum fragmentation, and cellular protein quantity/localization) changes then determine an electrophysiological remodelling that also involves the autonomic nervous system. Finally, we summarize how EAT dysfunction may fit with the standard guidelines for AF. Lastly, we focus on the potential benefit of weight loss and different classes of CV drugs on EAT dysfunction, LA remodelling, and ultimately AF onset and recurrence.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2022. For permissions, please email: journals.permissions@oup.com.

Europace: 10 Mar 2022; epub ahead of print
Poggi AL, Gaborit B, Schindler TH, Liberale L, Montecucco F, Carbone F
Europace: 10 Mar 2022; epub ahead of print | PMID: 35274140
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Preoperative Personalization of Atrial Fibrillation Ablation Strategy to Prevent Esophageal Injury: Impact of Changes in Esophageal Position.

Nakatani Y, Nuñez-Garcia M, Cheniti G, Sridi-Cheniti S, ... Jais P, Cochet H
Introduction
Due to changes in esophageal position, preoperative assessment of the esophageal location may not mitigate the risk of esophageal injury in catheter ablation for atrial fibrillation (AF). This study aimed to assess esophageal motion and its impact on AF ablation strategies.
Methods and results
Ninety-seven AF patients underwent 2 computed tomography (CT) scans. The area at risk of esophageal injury (AAR) was defined as the left atrial surface ≤3 mm from the esophagus. On CT1, ablation lines were drawn blinded to the esophageal location to create 3 ablation sets: individual pulmonary vein isolation (PVI), wide antral circumferential ablation (WACA), and WACA with linear ablation (WACA+L). Thereafter, ablation lines for WACA and WACA+L were personalized to avoid the AAR. Rigid registration was performed to align CT1 onto CT2, and the relationship between ablation lines and the AAR on CT2 was analyzed. The esophagus moved by 3.6 [2.7 to 5.5] mm. The AAR on CT2 was 8.6 ± 3.3 cm2 , with 77% overlapping that on CT1. High body mass index was associated with the AAR mismatch (standardized β 0.382, P <0.001). Without personalization, AARs on ablation lines for individual PVI, WACA, and WACA+L were 0 [0-0.4], 0.8 [0.5-1.2], 1.7 [1.2-2.0] cm2 . Despite the esophageal position change, the personalization of ablation lines for WACA and WACA+L reduced the AAR on lines to 0 [0-0.5] and 0.7 [0.3-1.0] cm2 (P <0.001 for both).
Conclusion
The personalization of ablation lines based on a preoperative CT reduced ablation to the AAR despite changes in esophageal position. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.

J Cardiovasc Electrophysiol: 10 Mar 2022; epub ahead of print
Nakatani Y, Nuñez-Garcia M, Cheniti G, Sridi-Cheniti S, ... Jais P, Cochet H
J Cardiovasc Electrophysiol: 10 Mar 2022; epub ahead of print | PMID: 35274776
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Smartphone detection of atrial fibrillation using photoplethysmography: a systematic review and meta-analysis.

Gill S, Bunting KV, Sartini C, Cardoso VR, ... Gkoutos GV, Kotecha D
Objectives
Timely diagnosis of atrial fibrillation (AF) is essential to reduce complications from this increasingly common condition. We sought to assess the diagnostic accuracy of smartphone camera photoplethysmography (PPG) compared with conventional electrocardiogram (ECG) for AF detection.
Methods
This is a systematic review of MEDLINE, EMBASE and Cochrane (1980-December 2020), including any study or abstract, where smartphone PPG was compared with a reference ECG (1, 3 or 12-lead). Random effects meta-analysis was performed to pool sensitivity/specificity and identify publication bias, with study quality assessed using the QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies-2) risk of bias tool.
Results
28 studies were included (10 full-text publications and 18 abstracts), providing 31 comparisons of smartphone PPG versus ECG for AF detection. 11 404 participants were included (2950 in AF), with most studies being small and based in secondary care. Sensitivity and specificity for AF detection were high, ranging from 81% to 100%, and from 85% to 100%, respectively. 20 comparisons from 17 studies were meta-analysed, including 6891 participants (2299 with AF); the pooled sensitivity was 94% (95% CI 92% to 95%) and specificity 97% (96%-98%), with substantial heterogeneity (p<0.01). Studies were of poor quality overall and none met all the QUADAS-2 criteria, with particular issues regarding selection bias and the potential for publication bias.
Conclusion
PPG provides a non-invasive, patient-led screening tool for AF. However, current evidence is limited to small, biased, low-quality studies with unrealistically high sensitivity and specificity. Further studies are needed, preferably independent from manufacturers, in order to advise clinicians on the true value of PPG technology for AF detection.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Heart: 10 Mar 2022; epub ahead of print
Gill S, Bunting KV, Sartini C, Cardoso VR, ... Gkoutos GV, Kotecha D
Heart: 10 Mar 2022; epub ahead of print | PMID: 35277454
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study.

Komen JJ, Pottegård A, Mantel-Teeuwisse AK, Forslund T, ... Kjerpeseth LJ, Klungel OH
Aims
There is currently no consensus on whether atrial fibrillation (AF) patients at low risk for stroke (one non-sex-related CHA2DS2-VASc point) should be treated with an oral anticoagulant.
Methods and results
We conducted a multi-country cohort study in Sweden, Denmark, Norway, and Scotland. In total, 59 076 patients diagnosed with AF at low stroke risk were included. We assessed the rates of stroke or major bleeding during treatment with a non-vitamin K antagonist oral anticoagulant (NOAC), a vitamin K antagonist (VKA), or no treatment, using inverse probability of treatment weighted (IPTW) Cox regression. In untreated patients, the rate for ischaemic stroke was 0.70 per 100 person-years and the rate for a bleed was also 0.70 per 100 person-years. Comparing NOAC with no treatment, the stroke rate was lower [hazard ratio (HR) 0.72; 95% confidence interval (CI) 0.56-0.94], and the rate for intracranial haemorrhage (ICH) was not increased (HR 0.84; 95% CI 0.54-1.30). Comparing VKA with no treatment, the rate for stroke tended to be lower (HR 0.81; 95% CI 0.59-1.09), and the rate for ICH tended to be higher during VKA treatment (HR 1.37; 95% CI 0.88-2.14). Comparing NOAC with VKA treatment, the rate for stroke was similar (HR 0.92; 95% CI 0.70-1.22), but the rate for ICH was lower during NOAC treatment (HR 0.63; 95% CI 0.42-0.94).
Conclusion
These observational data suggest that NOAC treatment may be associated with a positive net clinical benefit compared with no treatment or VKA treatment in patients at low stroke risk, a question that can be tested through a randomized controlled trial.
Key question
What is the association between anticoagulant treatment and stroke and bleeding rate, in patients with one non-sex-related risk factor for stroke?
Key findings

Take-home message
These observational data suggest that NOAC treatment may be associated with a positive net clinical benefit compared with no treatment or VKA treatment in patients at low stroke risk, a hypothesis that can be tested through a randomized controlled trial.

© The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology.

Eur Heart J: 09 Mar 2022; epub ahead of print
Komen JJ, Pottegård A, Mantel-Teeuwisse AK, Forslund T, ... Kjerpeseth LJ, Klungel OH
Eur Heart J: 09 Mar 2022; epub ahead of print | PMID: 35265981
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Evaluation of antithrombotic use and COVID-19 outcomes in a nationwide atrial fibrillation cohort.

Handy A, Banerjee A, Wood AM, Dale C, ... Sofat R, CVD-COVID-UK Consortium
Objective
To evaluate antithrombotic (AT) use in individuals with atrial fibrillation (AF) and at high risk of stroke (CHA2DS2-VASc score ≥2) and investigate whether pre-existing AT use may improve COVID-19 outcomes.
Methods
Individuals with AF and CHA2DS2-VASc score ≥2 on 1 January 2020 were identified using electronic health records for 56 million people in England and were followed up until 1 May 2021. Factors associated with pre-existing AT use were analysed using logistic regression. Differences in COVID-19-related hospitalisation and death were analysed using logistic and Cox regression in individuals with pre-existing AT use versus no AT use, anticoagulants (AC) versus antiplatelets (AP), and direct oral anticoagulants (DOACs) versus warfarin.
Results
From 972 971 individuals with AF (age 79 (±9.3), female 46.2%) and CHA2DS2-VASc score ≥2, 88.0% (n=856 336) had pre-existing AT use, 3.8% (n=37 418) had a COVID-19 hospitalisation and 2.2% (n=21 116) died, followed up to 1 May 2021. Factors associated with no AT use included comorbidities that may contraindicate AT use (liver disease and history of falls) and demographics (socioeconomic status and ethnicity). Pre-existing AT use was associated with lower odds of death (OR=0.92, 95% CI 0.87 to 0.96), but higher odds of hospitalisation (OR=1.20, 95% CI 1.15 to 1.26). AC versus AP was associated with lower odds of death (OR=0.93, 95% CI 0.87 to 0.98) and higher hospitalisation (OR=1.17, 95% CI 1.11 to 1.24). For DOACs versus warfarin, lower odds were observed for hospitalisation (OR=0.86, 95% CI 0.82 to 0.89) but not for death (OR=1.00, 95% CI 0.95 to 1.05).
Conclusions
Pre-existing AT use may be associated with lower odds of COVID-19 death and, while not evidence of causality, provides further incentive to improve AT coverage for eligible individuals with AF.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Heart: 09 Mar 2022; epub ahead of print
Handy A, Banerjee A, Wood AM, Dale C, ... Sofat R, CVD-COVID-UK Consortium
Heart: 09 Mar 2022; epub ahead of print | PMID: 35273122
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Anatomy of the Proximal Septal Vein in Patients with Focal Intramural Ventricular Arrhythmias.

Tam TK, Liang JJ, Ghannam M, Latchamsetty R, ... Morady F, Bogun F
Background
Focal ventricular arrhythmias (VA) originating from the intramural myocardium of the basal septum are difficult to localize and ablate. Proximal septal veins emptying into the great cardiac vein can reach close to the origin of intramural arrhythmias.
Objective
To assess characteristics of proximal septal coronary veins in patients with intramural VAs.
Methods and results
From among 84 consecutive patients with intramural VAs, 29 patients (age 60±11years, 16 males, ejection fraction 47±13%) underwent preprocedural cardiac computed tomographic angiography (CTA). In 14 of these patients the intramural site of origin (SOO) was identified with multipolar catheters. The intramural SOO could not be accessed with mapping catheters in the other 15 patients while mapping the coronary venous system. The CTA identified sizable proximal septal veins in all patients in whom the SOO could be accessed with mapping catheters. In the patients in whom the intramural SOO was not identified, the proximal septal veins were often either small (< 2 mm at branching site) or non-existent (n=9, p=0.001). The proximal septal veins in patients in whom the SOO was identified were larger than in the patients in whom the SOO could not be identified (3.0±0.6 mm vs 2.1±0.9 mm, p=0.01).
Conclusions
Preprocedural imaging with CTAs can be beneficial in identifying the anatomy of proximal septal coronary veins that allow adequate mapping of patients with suspected intramural VAs. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.

J Cardiovasc Electrophysiol: 08 Mar 2022; epub ahead of print
Tam TK, Liang JJ, Ghannam M, Latchamsetty R, ... Morady F, Bogun F
J Cardiovasc Electrophysiol: 08 Mar 2022; epub ahead of print | PMID: 35262245
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Genetically Based Atrial Fibrillation: Current Considerations for Diagnosis and Management.

Pensa AV, Baman JR, Puckelwartz MJ, Wilcox JE
Atrial fibrillation (AF) is the most common atrial arrhythmia and is subcategorized into numerous clinical phenotypes. Given its heterogeneity, investigations into the genetic mechanisms underlying AF have been pursued in recent decades, with predominant analyses focusing on early onset or lone AF. Linkage analyses, genome wide association studies (GWAS), and single gene analyses have led to the identification of rare and common genetic variants associated with AF risk. Significant overlap with genetic variants implicated in dilated cardiomyopathy syndromes, including truncating variants of the sarcomere protein titin, have been identified through these analyses, in addition to other genes associated with cardiac structure and function. Despite this, widespread utilization of genetic testing in AF remains hindered by the unclear impact of genetic risk identification on clinical outcomes and the high prevalence of variants of unknown significance (VUS). However, genetic testing is a reasonable option for patients with early onset AF and in those with significant family history of arrhythmia. While many knowledge gaps remain, emerging data support genotyping to inform selection of AF therapeutics. In this review we highlight the current understanding of the complex genetic basis of AF and explore the overlap of AF with inherited cardiomyopathy syndromes. We propose a set of criteria for clinical genetic testing in AF patients and outline future steps for the integration of genetics into AF care. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.

J Cardiovasc Electrophysiol: 08 Mar 2022; epub ahead of print
Pensa AV, Baman JR, Puckelwartz MJ, Wilcox JE
J Cardiovasc Electrophysiol: 08 Mar 2022; epub ahead of print | PMID: 35262243
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

In vivo Lesion Index (LSI) validation in percutaneous radiofrequency catheter ablation.

Themistoclakis S, Calzolari V, De Mattia L, China P, ... Thiene G, Tondo C
Introduction
Lesion Index (LSI) has been developed to predict lesion efficacy during radiofrequency (RF) catheter ablation. However, its value in predicting lesions size has still to be established. The aim of our study was to assess the lesions size reproducibility for pre-specified values of LSI reached during RF delivery in an in vivo beating heart.
Methods
Ablation lesions were created with different values of LSI in 7 domestic pigs by means of a contact force sensing catheter (TactiCathTM , Abbott). Lesions were identified during RF delivery by means of a 3D mapping system (EnSiteTM Precision, Abbott) and measured after heart explantation. Histology was carried out after gross examination on the first 3 lesions to confirm the accuracy of the macroscopic evaluation.
Results
A total of 64 myocardial lesions were created. Thirty-nine lesions were excluded from the analysis for the following reasons: histological confirmation of macroscopic lesion measurement (n=3), transmurality (n=24), unfavorable anatomic position (n=10), not macroscopically identifiable (n=2). In a final set of 25 non-transmural lesions, injury width and depth were respectively 4.6±0.6 mm and 2.6±0.8 mm for LSI=4, 7.3±0.8 mm and 4.7±0.6 mm for LSI=5, and 8.6±1.2 mm and 7.2±1.1 mm for LSI=6. A strong linear correlation was observed between LSI and lesion width (r=0.87, p<0.00001) and depth (r=0.89, p<0.00001). Multiple linear regression analysis identified LSI as the only ablation parameter that significantly predicted lesion width (p<0.001) and depth (p<0.001).
Conclusion
In our in vivo study, LSI proved highly predictive of lesion size and depth. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.

J Cardiovasc Electrophysiol: 08 Mar 2022; epub ahead of print
Themistoclakis S, Calzolari V, De Mattia L, China P, ... Thiene G, Tondo C
J Cardiovasc Electrophysiol: 08 Mar 2022; epub ahead of print | PMID: 35262242
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Atrial Structural Remodeling in Patients With Atrial Fibrillation Is a Diffuse Fibrotic Process: Evidence From High-Density Voltage Mapping and Atrial Biopsy.

Yamaguchi T, Otsubo T, Takahashi Y, Nakashima K, ... Takahashi N, Node K

Background:
Low-voltage areas (LVAs) in the atria of patients with atrial fibrillation are considered local fibrosis. We hypothesized that voltage reduction in the atria is a diffuse process associated with fibrosis and that the presence of LVAs reflects a global voltage reduction. Methods and Results We examined 140 patients with atrial fibrillation and 13 patients with a left accessory pathway (controls). High-density bipolar voltage mapping was performed using a grid-mapping catheter during high right atrial pacing. Global left atrial (LA) voltage (VGLA) in the whole LA and regional LA voltage (VRLA) in 6 anatomic regions were evaluated with the mean of the highest voltage at a sampling density of 1 cm2. Patients with atrial fibrillation were categorized into quartiles by VGLA. LVAs were evaluated at voltage cutoffs of 0.1, 0.5, 1.0, and 1.5 mV. Twenty-eight patients with atrial fibrillation also underwent right atrial septum biopsy, and the fibrosis extent was quantified. Voltage at the biopsy site (Vbiopsy) was recorded. VGLA results by category were Q1 (<4.2 mV), Q2 (4.2-5.6 mV), Q3 (5.7-7.0 mV), and Q4 (≥7.1 mV). VRLA at any region was reduced as VGLA decreased. VGLA and VRLA did not differ between Q4 and controls. The presence of LVAs increased as VGLA decreased at any voltage cutoff. Biopsies revealed 11±6% fibrosis, which was inversely correlated with both Vbiopsy and VGLA (r=-0.71 and -0.72, respectively). Vbiopsy was correlated with VGLA (r=0.82).
Conclusions:
Voltage reduction in the LA is a diffuse process associated with fibrosis. Presence of LVAs reflects diffuse voltage reduction of the LA.




J Am Heart Assoc: 08 Mar 2022:e024521; epub ahead of print
Yamaguchi T, Otsubo T, Takahashi Y, Nakashima K, ... Takahashi N, Node K
J Am Heart Assoc: 08 Mar 2022:e024521; epub ahead of print | PMID: 35261287
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Trimetazidine Alleviates Postresuscitation Myocardial Dysfunction and Improves 96-Hour Survival in a Ventricular Fibrillation Rat Model.

Li J, Qi Y, Wang J, Dai C, Chen B, Li Y

Background:
Myocardial dysfunction is a critical cause of post-cardiac arrest hemodynamic instability and circulatory failure that may lead to early mortality after resuscitation. Trimetazidine is a metabolic agent that has been demonstrated to provide protective effects in myocardial ischemia. However, whether trimetazidine protects against postresuscitation myocardial dysfunction is unknown. Methods and Results Cardiopulmonary resuscitation was initiated after 8 minutes of untreated ventricular fibrillation in Sprague-Dawley rats. Animals were randomized to 4 groups immediately after resuscitation (n=15/group): (1) normothermia control (NTC); (2) targeted temperature management; (3) trimetazidine-normothermia; (4) trimetazidine-targeted temperature management. TMZ was administered at a single dose of 10 mg/kg in rats with trimetazidine. The body temperature was maintained at 34.0°C for 2 hours and then rewarmed to 37.5°C in rats with targeted temperature management. Postresuscitation hemodynamics, 96-hours survival, and pathological analysis were assessed. Heart tissues and blood samples of additional rats (n=6/group) undergoing the same experimental procedure were collected to measure myocardial injury, inflammation and oxidative stress-related biomarkers with ELISA-based quantification assays. Compared with normothermia control, tumor necrosis factor-α, and cardiac troponin-I were significantly reduced, whereas the left ventricular ejection fraction and 96-hours survival rates were significantly improved in the 3 experimental groups. Furthermore, inflammation and oxidative stress-related biomarkers together with collagen volume fraction were significantly decreased in rats undergoing postresuscitation interventions.
Conclusions:
Trimetazidine significantly alleviates postresuscitation myocardial dysfunction and improves survival by decreasing oxidative stress and inflammation in a ventricular fibrillation rat model. A single dose of trimetazidine administrated immediately after resuscitation can effectively improve cardiac function, whether used alone or combined with targeted temperature management.




J Am Heart Assoc: 08 Mar 2022:e023378; epub ahead of print
Li J, Qi Y, Wang J, Dai C, Chen B, Li Y
J Am Heart Assoc: 08 Mar 2022:e023378; epub ahead of print | PMID: 35261264
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

CHARACTERIZATION OF THE RIGHT VENTRICULAR SUBSTRATE PARTICIPATING IN POST INFARCTION VENTRICULAR TACHYCARDIA.

Walsh KA, Daw JM, Lin A, Guandalini G, ... Marchlinski FE, Santangeli P
Background
The right ventricle (RV) is uncommonly implicated in post-infarction ventricular tachycardia (VT). The prevalence and features of RV substrate participating in post-infarction VT are undefined.
Objectives
To characterize critical RV substrate (CRVS) involvement in patients with post-infarction VT.
Methods
We retrospectively reviewed 1279 patients with post-infarction VT undergoing catheter ablation at our center from January 2000 through May 2020. Cases with CRVS defined by conclusive demonstration of participation in VT with activation, entrainment and/or pace mapping during sinus rhythm were identified.
Results
CRVS was identified in 27/1279 (2.1%), age 65±13 years, 96% males, median LV EF 25%, 93% with LBBB morphology VT. CRVS was identified by RV activation and/or entrainment mapping (n=19) or by presence of low-voltage abnormal electrograms with excellent pace-map for the targeted VT and non-inducibility following ablation (n=8). VT termination during RV ablation occurred in 15 patients. After a median follow-up of 20 months (interquartile range 9-53 months) and a median of 2 procedures (interquartile range 1-3), 22/27 (80%) patients had no VT recurrence and 11 (41%) died.
Conclusion
The RV contains critical substrate elements of post-infarction VT in at least 2.1% of cases. RV mapping should be considered in cases where LV mapping fails to demonstrate adequate targets, particularly in patients with LBBB morphology VT.

Copyright © 2022. Published by Elsevier Inc.

Heart Rhythm: 08 Mar 2022; epub ahead of print
Walsh KA, Daw JM, Lin A, Guandalini G, ... Marchlinski FE, Santangeli P
Heart Rhythm: 08 Mar 2022; epub ahead of print | PMID: 35276321
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Intramyocardial mapping of ventricular premature depolarizations via septal venous perforators: Differentiating the superior intraseptal region from left ventricular summit origins.

Guandalini GS, Santangeli P, Schaller R, Pothineni NVK, ... Marchlinski FE, Garcia FC
Background
The intramyocardial aspect of the left ventricular summit (LVS) can be mapped by advancing a unipolar guidewire into septal perforator branches of the anterior intraventricular vein (AIV).
Objective
To differentiate between ventricular premature depolarizations (VPDs) with a basal superior intraseptal (SIS) site of origin and those originating from the epicardial LVS using septal intramyocardial mapping.
Methods
A retrospective cohort of patients with suspected LVS VPDs who underwent SIS unipolar mapping were reviewed for their clinical characteristics, mapping findings and procedural outcomes.
Results
SIS mapping was successful in 44 out of 47 cases (93.6%). VPD origin was SIS (defined as earliest activation from intraseptal wire) in 20 patients (45.5%, median 23ms pre-QRS). Procedural success was similar in patients with (group 1) and without (group 2) SIS origin (respectively, 84% vs. 87.5%, p = 0.842). Of the 10 patients in group 1 without pre-systolic endocardial activation, 5 (11.3% of all 44 cases) were successfully ablated from the LV endocardium, using an anatomical approach targeting the endocardium closest to the earliest intraseptal activation site.
Conclusion
A significant proportion, 45.5%, of VPDs that appear to arise from the LV summit can be demonstrated to have a SIS origin using septal perforator venous mapping. A significant minority (11.3%) of these can be ablated from the endocardium by targeting from an anatomic vantage point closest to the earliest intraseptal activation site. The described strategy may help differentiate true LVS VPDs from those with SIS sites of origin.

Copyright © 2022. Published by Elsevier Inc.

Heart Rhythm: 08 Mar 2022; epub ahead of print
Guandalini GS, Santangeli P, Schaller R, Pothineni NVK, ... Marchlinski FE, Garcia FC
Heart Rhythm: 08 Mar 2022; epub ahead of print | PMID: 35278700
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Disentangling the association between kidney function and atrial fibrillation: A bidirectional Mendelian randomization study.

Geurts S, van der Burgh AC, Bos MM, Ikram MA, ... Chaker L, Kavousi M
Background
The potential bidirectional causal association between kidney function and atrial fibrillation (AF) remains unclear.
Methods
We conducted a bidirectional two-sample Mendelian randomization (MR) analysis. From multiple genome-wide association studies (GWAS), we retrieved genetic variants associated with kidney function (estimated glomerular filtration rate based on creatinine (eGFRcreat), blood urea nitrogen (BUN), chronic kidney disease (CKD stage ≥G3): n = 1,045,620, eGFR based on cystatin C: n = 24,063-32,861, urine albumin to creatinine ratio (UACR), and microalbuminuria: n = 564,257), and AF (n = 1,030,836). The inverse-variance weighted method was used as our main analyses.
Results
MR analyses supported a causal effect of CKD (n = 9 SNPs, odds ratio (OR): 1.10, 95% confidence interval (CI): 1.04-1.17, p-value = 1.97 × 10-03), and microalbuminuria (n = 5 SNPs, OR: 1.26, 95% CI: 1.10-1.46, p-value = 1.38 × 10-03) on AF risk. We also observed a causal effect of AF on eGFRcreat (n = 97 SNPs, OR: 1.00, 95% CI: 1.00-1.00, p-value = 6.78 × 10-03), CKD (n = 107 SNPs, OR: 1.06, 95% CI: 1.03-1.09, p-value = 2.97 × 10-04), microalbuminuria (n = 83 SNPs, OR: 1.07, 95% CI: 1.04-1.09, p-value = 2.49 × 10-08), and a suggestive causal effect on eGFRcys (n = 103 SNPs, OR: 0.99, 95% CI: 0.99-1.00, p-value = 4.61 × 10-02). Sensitivity analyses, including weighted median estimator, MR-Egger, the MR pleiotropy residual sum and outlier test, and excluding genetic variants associated with possible confounders and/or horizontal mediators (myocardial infarction/coronary artery disease, heart failure) indicated that these findings were robust.
Conclusions
Our results indicated a bidirectional causal association between kidney function and AF. The shared genetic architecture between kidney dysfunction and AF might represent potential important therapeutic targets to prevent both conditions in the general population.

Copyright © 2022. Published by Elsevier B.V.

Int J Cardiol: 08 Mar 2022; epub ahead of print
Geurts S, van der Burgh AC, Bos MM, Ikram MA, ... Chaker L, Kavousi M
Int J Cardiol: 08 Mar 2022; epub ahead of print | PMID: 35278573
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Association between ventricular repolarization parameters and cardiovascular death in patients of the SWISS-AF cohort.

Rivolta MW, Mainardi LT, Laureanti R, Sassi R, ... Auricchio A, Corino VDA
Background
The effect of the ventricular repolarization heterogeneity has not been systematically assessed in patients with atrial fibrillation (AF). Aim of this study is to assess ventricular repolarization heterogeneity as predictor of cardiovascular (CV) death and/or other CV events in patients with AF.
Methods
From the multicenter prospective Swiss-AF (Swiss Atrial Fibrillation) Cohort Study, we enrolled 1711 patients who were in sinus rhythm (995) or AF (716). Resting ECG recordings of 5-min duration were obtained at baseline. Parameters assessing ventricular repolarization were computed (QTc, Tpeak-Tend, J-Tpeak and V-index).
Results
During AF, the V-index was found repeatable (no differences when computed over the whole recording, on the first 2.5-min and on the last 2.5-min segments). During a mean follow-up time of 2.6 ± 1.0 years, 90 patients died for CV reasons. In bivariate Cox regression analysis (adjusted for age only), the V-index was associated with an increased risk of CV death, both in the subgroup of patients in sinus rhythm (SR) as well as those in AF. In multivariate analysis adjusted for clinical risk factors and medications, both prolonged QTc and V-index were independently associated with an increased risk of CV death (QTc: hazard ratio [HR] 2.78, 95% CI 1.79-4.32, p < 0.001; V-index: HR 1.73, 95% CI 1.12-2.69, p = 0.014).
Conclusions
QTc and V-index, measured in a single 5-min ECG recording, were independent predictors of CV death in a cohort of patients with AF and might be a valuable tool for further risk stratification to guide patient management. Clinical Trial Identifier Swiss-AF study: NCT02105844.

Copyright © 2022. Published by Elsevier B.V.

Int J Cardiol: 08 Mar 2022; epub ahead of print
Rivolta MW, Mainardi LT, Laureanti R, Sassi R, ... Auricchio A, Corino VDA
Int J Cardiol: 08 Mar 2022; epub ahead of print | PMID: 35278571
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Artificial Intelligence and Atrial Fibrillation.

Sehrawat O, Kashou AH, Noseworthy PA
In the context of atrial fibrillation (AF), traditional clinical practices have thus far fallen short in several domains such as identifying patients at risk of incident AF or patients with concomitant undetected paroxysmal AF. Novel approaches leveraging artificial intelligence have the potential to provide new tools to deal with some of these old problems. In this review we focus on the roles of artificial intelligence-enabled ECG pertaining to AF, potential roles of deep learning (DL) models in the context of current knowledge gaps, as well as limitations of these models. One key area where DL models can translate to better patient outcomes is through automated ECG interpretation. Further, we overview some of the challenges facing AF screening and the harms and benefits of screening. In this context, a unique model was developed to detect underlying hidden AF from sinus rhythm and is discussed in detail with its potential uses. Knowledge gaps also remain regarding the best ways to monitor patients with embolic stroke of undetermined source (ESUS) and who would benefit most from oral anticoagulation. The AI-enabled AF model is one potential way to tackle this complex problem as it could be used to identify a subset of high-risk ESUS patients likely to benefit from empirical oral anticoagulation. Role of DL models assessing AF burden from long duration ECG data is also discussed as a way of guiding management. There is a trend towards the use of consumer-grade wristbands and watches to detect AF from photoplethysmography data. However, ECG currently remains the gold standard to detect arrythmias including AF. Lastly, role of adequate external validation of the models and clinical trials to study true performance is discussed. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.

J Cardiovasc Electrophysiol: 07 Mar 2022; epub ahead of print
Sehrawat O, Kashou AH, Noseworthy PA
J Cardiovasc Electrophysiol: 07 Mar 2022; epub ahead of print | PMID: 35258136
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Strategies for Repeat Ablation for Atrial Fibrillation: A Multicentre Comparison of Non-Pulmonary Vein versus Pulmonary Vein Target Ablation.

Mol D, Mulder MJ, Veenstra R, Allaart CP, ... de Groot JR, de Jong JSSG
Introduction
Approximately 18% of patients with atrial fibrillation (AF) undergo a repeat ablation within 12 months after their index ablation. Despite the high prevalence, comparative studies on non-pulmonary vein (PV) target strategies in repeat AF ablation are scarce. Here, we describe 12 months efficacy of non-PV and PV target ablations as repeat ablation strategy.
Methods
A multicentre retrospective, descriptive study was conducted with data of 280 patients who underwent repeat AF ablation. Ablation strategy for repeat ablation was at operators\' discretion. Non-PV target ablation (n=140) included, PV re-isolation, posterior wall isolation, mitral line, roofline and/or complex fractionated atrial electrogram ablation. PV target ablation (n=140), included re-isolation and/or wide atrium circumferential ablation. Patients\' demographics and rhythm outcomes during 12-months follow-up were analysed.
Results
At 12 months, more atrial tachyarrhythmias were observed in the non-PV target group (48.6%) compared to the PV target group (29.3%,p=0.001). Similarly, a significantly higher AF and atrial tachycardia (AT) recurrence rate was observed after non-PV target ablation compared to PV target ablation (36.4% versus 22.1% and 22.9% versus 10.7%). After adjustment, a significantly higher risk of AT recurrence remained in the non-PV target group. Both groups significantly de-escalated anti-arrhythmic drug use, de-escalation was more profound after PV target ablation. Patients with isolated PVs during non-PV target ablation had a significantly higher risk for AF recurrence than those with reconnected PVs.
Conclusion
Compared to PV target ablation, non-PV target repeat ablation did not improve outcomes after 12 months, and was independently associated an increased risk for AT recurrences. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.

J Cardiovasc Electrophysiol: 07 Mar 2022; epub ahead of print
Mol D, Mulder MJ, Veenstra R, Allaart CP, ... de Groot JR, de Jong JSSG
J Cardiovasc Electrophysiol: 07 Mar 2022; epub ahead of print | PMID: 35257441
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Remote and Wearable ECG Devices with Diagnostic Abilities in Adults: A State-of-the-Science Scoping Review.

Bouzid Z, Al-Zaiti SS, Bond R, Sejdic E
The electrocardiogram (ECG) records the electrical activity in the heart in real-time, providing an important opportunity to detecting various cardiac pathologies. The 12-lead ECG currently serves as the \"standard\" ECG acquisition technique for diagnostic purposes for many cardiac pathologies other than arrhythmias. However, the technical aspects of acquiring a 12-lead ECG are not easy and its usage is currently restricted to trained medical personnel, limiting the scope of its usefulness. Remote and wearable ECG devices have attempted to bridge this gap by enabling patients to take their own ECG using a simplified method at the expense of a reduced number of leads, usually a single-lead ECG. In this review article, we summarize the studies which investigate the use of remote ECG devices and their clinical utility in diagnosing cardiac pathologies. Eligible studies discussed FDA-cleared, commercially available devices that were validated on an adult population. We summarize technical logistics of signal quality and device reliability, dimensional and functional features, and diagnostic value. In summary, our synthesis shows that reduced-set ECG wearables have huge potential for long-term monitoring, particularly if paired with real-time notification techniques. Such capabilities make them primarily useful for abnormal rhythm detection and there is sufficient evidence that a remote ECG device can be more superior to traditional 12-lead ECG in diagnosing specific arrhythmias such as atrial fibrillation. However, this review identifies important challenges faced by this technology, highlighting the limited availability of clinical research examining their usefulness.

Copyright © 2022 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Heart Rhythm: 07 Mar 2022; epub ahead of print
Bouzid Z, Al-Zaiti SS, Bond R, Sejdic E
Heart Rhythm: 07 Mar 2022; epub ahead of print | PMID: 35276320
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Watchman FLX vs. Watchman 2.5 in a Dual-Center Left Atrial Appendage Closure Cohort: the WATCH-DUAL study.

Galea R, Mahmoudi K, Gräni C, Elhadad S, ... Amabile N, Räber L
Aims
No studies have compared Watchman 2.5 (W2.5) with Watchman FLX (FLX) devices to date. We aimed at comparing the FLX with W2.5 devices with respect to clinical outcomes, left atrial appendage (LAA) sealing properties and device-related thrombus (DRT).
Methods and results
All consecutive left atrial appendage closure (LAAC) procedures performed at two European centres between November 2017 and February 2021 were included. Procedure-related complications and net adverse cardiovascular events (NACE) at 6 months after LAAC were recorded. At 45-day computed tomography (CT) follow-up, intra- (IDL) and peri- (PDL) device leak, residual patent neck area (RPNA), and DRT were assessed by a Corelab. Out of 144 LAAC consecutive procedures, 71 and 73 interventions were performed using W2.5 and FLX devices, respectively. There were no differences in terms of procedure-related complications (4.2% vs. 2.7%, P = 0.626). At 45-day CT, the FLX was associated with lower frequency of IDL [21.3% vs. 40.0%; P = 0.032; odds ratio (OR): 0.375; 95% confidence interval (CI): 0.160-0.876; P = 0.024], similar rate of PDL (29.5% vs. 42.0%; P = 0.170), and smaller RPNA [6 (0-36) vs. 40 (6-115) mm2; P = 0.001; OR: 0.240; 95% CI: 0.100-0.577; P = 0.001] compared with the W2.5 group. At 45 days, rate of DRT as detected by CT and/or transoesophageal echocardiography (TOE), was higher with W2.5 (6.0% vs. 0%, P = 0.045). At 6-month follow-up, NACE did not differ between groups.
Conclusions
In this cohort of consecutive LAACs, FLX as compared to W2.5, was associated with similar procedure-related complications and 6-month NACE, but with improved LAA neck coverage, and lower IDL and DRT.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2022. For permissions, please email: journals.permissions@oup.com.

Europace: 06 Mar 2022; epub ahead of print
Galea R, Mahmoudi K, Gräni C, Elhadad S, ... Amabile N, Räber L
Europace: 06 Mar 2022; epub ahead of print | PMID: 35253840
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Sedentary Behavior and Atrial Fibrillation in Older Women: The OPACH Study.

Boursiquot BC, Bellettiere J, LaMonte MJ, LaCroix AZ, Perez MV

Background:
Sedentary behavior is associated with cardiovascular disease, but its association with incident atrial fibrillation is not well studied. Our aim was to measure the association between objectively measured sedentary behavior and incident atrial fibrillation. Methods and Results Sedentary behavior was measured by a triaxial accelerometer worn on a belt for 1 week. Incident atrial fibrillation was ascertained from Medicare claims. The associations between total sedentary time (or patterns of sedentary behavior) and incident atrial fibrillation were assessed using Cox proportional hazards models adjusted for demographic and clinical covariates. Among 2675 participants (mean age, 78.2 years), there were 268 (10.0%) cases of incident atrial fibrillation at a rate of 31 cases per 1000 person-years. Greater total sedentary time was associated with a higher risk of incident atrial fibrillation after adjustment for age, race and ethnicity, body mass index, education, smoking history, hypertension, diabetes, stroke, heart disease, and other chronic conditions (quartile 4 versus quartile 1: hazard ratio, 1.20, [95% CI, 0.81-1.78]; P for trend=0.05). After adjusting for physical function and self-rated health, this was no longer statistically significant. Both longer mean sedentary bout duration and more continuous sedentary periods (versus frequent breaks in sedentary time) were also associated with higher risks of incident atrial fibrillation, but these associations were also attenuated with serial adjustment.
Conclusions:
Total sedentary time and prolonged patterns of sedentary accumulation were associated with a higher risk of atrial fibrillation in this prospective study of community-dwelling older women, but these associations were attenuated by adjustment for physical function and self-reported health. This suggests that associations between sedentary behavior and atrial fibrillation may be attributable to global measures of overall function and health.




J Am Heart Assoc: 04 Mar 2022:e023833; epub ahead of print
Boursiquot BC, Bellettiere J, LaMonte MJ, LaCroix AZ, Perez MV
J Am Heart Assoc: 04 Mar 2022:e023833; epub ahead of print | PMID: 35253465
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Impact of oral anticoagulation on the association between frailty and clinical outcomes in people with atrial fibrillation: nationwide primary care records on treatment analysis.

Wilkinson C, Wu J, Clegg A, Nadarajah R, ... Todd O, Gale CP
Aims
People with atrial fibrillation (AF) frequently live with frailty, which increases the risk of mortality and stroke. This study reports the association between oral anticoagulation (OAC) and outcomes for people with frailty, and whether there is overall net benefit from treatment in people with AF.
Methods and results
Retrospective open cohort electronic records study. Frailty was identified using the electronic frailty index. Primary care electronic health records of 89 996 adults with AF and CHA2DS2-Vasc score of ≥2 were linked with secondary care and mortality data in the Clinical Practice Research Database (CPRD) from 1 January 1998 to 30 November 2018. The primary outcome was a composite of death, stroke, systemic embolism, or major bleeding. Secondary outcomes were stroke, major bleeding, all-cause mortality, transient ischaemic attack, and falls. Of 89 996 participants, 71 256 (79.2%) were living with frailty. The prescription of OAC increased with degree of frailty. For patients not prescribed OAC, rates of the primary outcome increased alongside frailty category. Prescription of OAC was associated with a reduction in the primary outcome for each frailty category [adjusted hazard ratio, 95% confidence interval, no OAC as reference; fit: vitamin K antagonist (VKA) 0.69, 0.64-0.75, direct oral anticoagulant (DOAC) 0.42, 0.33-0.53; mild frailty: VKA 0.52, 0.50-0.54, DOAC 0.57, 0.52-0.63; moderate: VKA 0.54, 0.52-0.56, DOAC 0.57, 0.52-0.63; severe: VKA 0.48, 0.45-0.51, DOAC 0.58, 0.52-0.65], with cumulative incidence function effects greater for DOAC than VKA.
Conclusion
Frailty among people with AF is common. The OAC was associated with a reduction in the primary endpoint across all degrees of frailty.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2022. For permissions, please email: journals.permissions@oup.com.

Europace: 03 Mar 2022; epub ahead of print
Wilkinson C, Wu J, Clegg A, Nadarajah R, ... Todd O, Gale CP
Europace: 03 Mar 2022; epub ahead of print | PMID: 35244709
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Epidemiology of cerebral microbleeds and risk of adverse outcomes in atrial fibrillation: a systematic review and meta-analysis.

Corica B, Romiti GF, Raparelli V, Cangemi R, Basili S, Proietti M
Aims
The aim of this study is to perform a systematic review and meta-analysis on the epidemiology of cerebral microbleeds (CMBs) and the risk of intracranial haemorrhage (ICH) and ischaemic stroke (IS) in patients with atrial fibrillation (AF).
Methods and results
PubMed and EMBASE databases were systematically searched from inception to 6 March 2021. All studies reporting the prevalence of CMBs and incidence of ICH and IS in AF patients with and without CMBs were included. Meta-analysis was conducted using random-effect models; odds ratios (ORs), 95% confidence intervals (CIs), and prediction intervals (PIs) were calculated for each outcome. Subgroup analyses were performed according to the number and localization of CMBs. A total of 562 studies were retrieved, with 17 studies finally included in the meta-analysis. Prevalence of CMBs in AF population was estimated at 28.3% (95% CI: 23.8-33.4%). Individuals with CMBs showed a higher risk of ICH (OR: 3.04, 95% CI: 1.83-5.06, 95% PI 1.23-7.49) and IS (OR: 1.78, 95% CI: 1.26-2.49, 95% PI 1.10-2.87). Patients with ≥5 CMBs showed a higher risk of ICH. Metaregression showed how higher of prevalence of diabetes mellitus in AF cohort is associated with higher prevalence of CMBs.
Conclusions
Cerebral microbleeds are common in patients with AF, found in almost one out of four subjects. Cerebral microbleeds were associated with both haemorrhagic and thromboembolic events in AF patients. Moreover, the risk of ICH increased consistently with the burden of CMBs. Cerebral microbleeds may represent an important overlooked risk factor for both ICH and IS in adults with AF.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2022. For permissions, please email: journals.permissions@oup.com.

Europace: 03 Mar 2022; epub ahead of print
Corica B, Romiti GF, Raparelli V, Cangemi R, Basili S, Proietti M
Europace: 03 Mar 2022; epub ahead of print | PMID: 35244694
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Prevalence and clinical significance of isolated low QRS voltages in young athletes.

Zorzi A, Bettella N, Tatangelo M, Del Monte A, ... Pelliccia A, Corrado D
Aims
Low QRS voltages (peak to peak <0.5 mV) in limb leads (LQRSV) on the athlete\'s electrocardiogram (ECG) may reflect an underlying cardiomyopathy, mostly arrhythmogenic cardiomyopathy (ACM) or non-ischaemic left ventricular scar (NILVS). We studied the prevalence and clinical meaning of isolated LQRSV in a large cohort of competitive athletes.
Methods and results
The index group included 2229 Italian competitive athletes [median age 18 years (16-25), 67% males, 97% Caucasian] without major ECG abnormalities at pre-participation screening. Three control groups included Black athletes (N = 1115), general population (N = 1115), and patients with ACM or NILVS (N = 58). Echocardiogram was performed in all athletes with isolated LQRSV and cardiac magnetic resonance (CMR) in those with ventricular arrhythmias or echocardiographic abnormalities. The isolated LQRSV pattern was found in 1.1% index athletes and was associated with increasing age (median age 28 vs. 18 years; P < 0.001), elite status (71% vs. 34%; P < 0.001), body surface area, and body mass index but not with sex, type of sport, and echocardiographic left ventricular mass. The prevalence of isolated LQRSV was 0.2% in Black athletes and 0.3% in young individuals from the general population. Cardiomyopathy patients had a significantly greater prevalence of isolated LQRSV (12%) than index athletes, Black athletes, and general population. Five index athletes with isolated LQSRV and exercise-induced ventricular arrhythmias underwent CMR showing biventricular ACM in 1 and idiopathic NILVS in 1.
Conclusions
Unlike cardiomyopathy patients, the ECG pattern of isolated LQRSV was rarely observed in athletes. This ECG sign should prompt clinical work-up for exclusion of an underlying cardiomyopathy.

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.

Europace: 03 Mar 2022; epub ahead of print
Zorzi A, Bettella N, Tatangelo M, Del Monte A, ... Pelliccia A, Corrado D
Europace: 03 Mar 2022; epub ahead of print | PMID: 35243505
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Association Between Biventricular Pacing and Incidence of Ventricular Arrhythmias in the Early Post-Operative Period after Left Ventricular Assist Device Implantation.

Chou A, Larson J, Deshmukh A, Cascino TM, ... Pagani FD, Liang JJ
Introduction
Cardiac resynchronization therapy (CRT) and left ventricular assist devices (LVAD) improve outcomes in heart failure patients. Early ventricular arrhythmias (VA) are common after LVAD and are associated with increased mortality. The association between left ventricular pacing (LVP) with CRT and VAs in the early post-LVAD period remains unclear.
Methods
This was a retrospective study of all patients undergoing LVAD implantation from 1/2016 - 12/2019. Patients were divided into those with CRT and active LVP (CRT-LVP) immediately post-LVAD implant versus those without CRT-LVP. ICD electrograms were reviewed and early VAs were defined as sustained VT/VF occurring within 30 days of LVAD implantation.
Results
Of 186 included patients (mean age 53 years, 75% male, mean BMI 28), 72 had CRT devices, 63 of whom had LV pacing enabled after LVAD implant (CRT-LVP group). Patients with CRT-LVP were more likely to have VA in the early post-operative period (21% vs 4%; p=0.0001). All 9 patients with CRT in whom LVP was disabled had no early VA. Among those with early VA, patients with CRT-LVP were more likely to have monomorphic VT (77% vs 40%; p=0.07). In multiple logistic regression, CRT-LVP pacing remained an independent predictor of early VA after adjustment for history of VA and AF.
Conclusions
Patients with CRT-LVP after LVAD implant had a higher incidence of early VA (specifically monomorphic VT). Epicardial LV pacing may be proarrhythmic in the early post-operative period after LVAD. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.

J Cardiovasc Electrophysiol: 03 Mar 2022; epub ahead of print
Chou A, Larson J, Deshmukh A, Cascino TM, ... Pagani FD, Liang JJ
J Cardiovasc Electrophysiol: 03 Mar 2022; epub ahead of print | PMID: 35245401
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Post-Intracranial Hemorrhage Antithrombotic Therapy in Patients With Atrial Fibrillation.

Lin SY, Chang YC, Lin FJ, Tang SC, Dong YH, Wang CC

Background:
To investigate the effectiveness and safety of withholding or restarting antithrombotic agents, and different antithrombotic therapies among patients with atrial fibrillation post-intracranial hemorrhage. Methods and Results This is a nationwide retrospective cohort study involving patients with atrial fibrillation receiving antithrombotic therapies who subsequently developed intracranial hemorrhage between January 1, 2011 and December 31, 2017. The risk of ischemic stroke (IS), recurrent intracerebral hemorrhage (ICH), and all-cause mortality were investigated between patients receiving no treatment versus patients reinitiating oral anticoagulants (OACs) or antiplatelet agents, and warfarin versus non-vitamin K antagonist OACs. We applied inverse probability of treatment weighting to balance the baseline characteristics and Cox proportional hazards model to estimate the hazard ratios (HRs) of different outcomes of interest. Compared with no treatment, OACs reduced the risk of IS (HR, 0.61; 0.42-0.89), without increase in the risk of ICH (1.15, 0.66-2.02); antiplatelet agent users showed a similar risk of IS (1.13, 0.81-1.56) and increased risk of ICH (1.81, 1.07-3.04). Use of OACs or antiplatelet agents did not reduce the risk of all-cause mortality (0.85, 0.72-1.01; and 0.88, 0.75-1.03, respectively). Compared with warfarin, non-vitamin K antagonist OAC users showed a similar risk of IS (0.92, 0.50-1.70), non-significantly reduced risk of ICH (0.53, 0.22-1.30), and significantly reduced all-cause mortality (0.60, 0.43-0.84).
Conclusions:
OACs are recommended in patients with atrial fibrillation and intracranial hemorrhage because they reduced the risk of IS with no increase in the risk of subsequent ICH. Non-vitamin K antagonist OACs are recommended over warfarin owing to their survival benefits.




J Am Heart Assoc: 03 Mar 2022:e022849; epub ahead of print
Lin SY, Chang YC, Lin FJ, Tang SC, Dong YH, Wang CC
J Am Heart Assoc: 03 Mar 2022:e022849; epub ahead of print | PMID: 35243876
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA-AF Phase III Registry.

Bayer V, Kotalczyk A, Kea B, Teutsch C, ... Lip GYH, Olshansky B

Background:
Effective stroke prevention with oral anticoagulants (OAC) is recommended for some patients with atrial fibrillation (AF). We aimed to describe OAC use by geographical region and type of site in patients with recent-onset AF enrolled in a large global registry. Methods and Results Eligible participants were recruited into GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation), a prospective observational cohort study from 2014 to 2016 in 4 international regions: North America, Europe, Asia, and Latin America. Cumulative incidence functions were generated for direct OACs (DOAC), vitamin K antagonists, and antiplatelet drugs considering competing risks, stratified by region and type of site. Time-to-treatment initiation after AF diagnosis was analyzed with Fine-Gray subdistribution hazard models. A total of 21 237 patients eligible for analysis were identified. By 30 days after AF diagnosis, 40%, 16%, and 8.6% of patients had DOAC, vitamin K antagonists, and antiplatelet drugs initiated, respectively. Earlier initiation of DOACs was observed in Europe, with Asia and Latin America having lower hazard rates of DOAC time-to-treatment initiation than Europe (hazard ratio [HR], 0.66; 95% CI, 0.62-0.70 and HR, 0.79; 95% CI, 0.73-0.85, respectively). DOAC initiation was highest in community hospitals, vitamin K antagonists in outpatient health care centers/anticoagulation clinics, and antiplatelet drugs in primary care clinics.
Conclusions:
Important geographic variability exists with the use of OACs for patients with AF. Differences in the time-to-treatment initiation of OAC by type of site suggests suboptimal implementation of guideline recommendations and could result in less benefit and more harm. Optimizing OAC use for patients with AF may improve outcomes and reduce health care costs. Registration URL: http://www.clinicaltrials.gov; Unique identifiers: NCT01468701, NCT01671007.




J Am Heart Assoc: 03 Mar 2022:e023907; epub ahead of print
Bayer V, Kotalczyk A, Kea B, Teutsch C, ... Lip GYH, Olshansky B
J Am Heart Assoc: 03 Mar 2022:e023907; epub ahead of print | PMID: 35243870
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Sex-related differences in the prognosis of patients with cardiac sarcoidosis treated with cardiac resynchronization therapy.

Nakasuka K, Ishibashi K, Hattori Y, Mori K, ... Ohte N, Kusano K
Background
Past studies showed the sex-related difference in the efficacy of cardiac resynchronization therapy (CRT). However, the data in cardiac sarcoidosis (CS) are limited.
Objective
To assess the sex-related prognostic differences in CS patients with CRT.
Methods
This multicenter CS survey included 430 patients (295 females) who met the diagnostic criteria of CS. Patients were divided into those treated with primary CRT or upgraded CRT from the pacemaker (CRT group, n=73) and others (control group, n=357). Sex differences in the incidence of all-cause death, heart failure (HF) death including heart transplantation, ventricular arrhythmia events (VAEs) (sudden death, appropriate device therapy), cardiac adverse events (CAEs) (HF death, VAEs), changes in serum brain natriuretic peptide (BNP) levels, and left ventricular ejection fraction (LVEF) over the follow-up were analyzed.
Results
During the median follow-up of 5.2 years, males, but not females, in the CRT group had significantly worse all-cause mortality than patients in the control group (p<0.001). In the CRT group, there was no significant sex-related difference in the incidence of HF death; however, females had significantly better VAEs- and CAEs-free survival than males (p=0.033, p=0.008, respectively). Multivariate analysis in the CRT group showed that female sex (hazard ratio 0.37, 95% confidence interval 0.15-0.89; p=0.026) independently predicted freedom from CAEs. During the follow-up, the BNP levels were significantly improved in all groups. LVEF was maintained in females with CRT.
Conclusions
In CS patients with CRT, HF death-free survival was similar between sexes. However, females exhibited better VAEs- and CAEs-free survival than males.

Copyright © 2022. Published by Elsevier Inc.

Heart Rhythm: 03 Mar 2022; epub ahead of print
Nakasuka K, Ishibashi K, Hattori Y, Mori K, ... Ohte N, Kusano K
Heart Rhythm: 03 Mar 2022; epub ahead of print | PMID: 35257978
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Transvenous Laser Lead Extraction in Patients with Congenital Complete Heart Block.

Darden D, Boateng BA, Tseng AS, Alshawabkeh L, ... Cha YM, Birgersdotter-Green U
Background
Data is lacking on lead management in patients with congenital complete heart block (CCHB) with cardiac implantable electronic devices (CIED).
Objective
This analysis sought to describe the natural history and outcomes in patients with CCHB with CIEDs undergoing transvenous lead extraction (TLE).
Methods
Data on all attempted TLE procedures in patients with CCHB at two institutions between 2011 and 2021 were collected from a retrospective registry.
Results
Overall, 16 patients (mean age at transvenous device implant: 13.8±4.7 years) were included. Before TLE, patients underwent an average of 2.25±1.3 generator changes, 3 (19%) underwent cardiac resynchronization therapy upgrade, and 7 (44%) underwent a lead revision with subsequently abandoned leads. Mean patient age at TLE was 34.4±9.4 years with a mean duration of lead implant of 19.2±6.9 years. Lead malfunction (n=11, 69%) and infection (n=5, 31%) were the most common indications for TLE. A total of 38 leads were removed with complete procedural success achieved in 14/16 (87.5%). Two (12.5%) major complications occurred, including right ventricular laceration and superior vena cava tear requiring sternotomies. All patients survived at one year follow-up.
Conclusion
Patients with CCHB represent a unique cohort highlighted by several generator changes, lead revisions, and abandoned leads at a young age, along with a long duration of lead dwelling time and a high prevalence of lead malfunction requiring TLE. There may be a high risk of major complications during TLE, suggesting TLE should only be performed in experienced centers. Larger studies are needed to confirm these findings.

Copyright © 2022. Published by Elsevier Inc.

Heart Rhythm: 03 Mar 2022; epub ahead of print
Darden D, Boateng BA, Tseng AS, Alshawabkeh L, ... Cha YM, Birgersdotter-Green U
Heart Rhythm: 03 Mar 2022; epub ahead of print | PMID: 35257976
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Age-related differences and associated mid-term outcomes of subcutaneous implantable cardioverter defibrillators: a propensity-matched analysis from a multicenter European registry.

Gulletta S, Gasperetti A, Schiavone M, Vogler J, ... Forleo GB, Tilz R
Background
A few limited case series have shown that the S-ICD system is safe in teenagers and young adults, but a large-scale analysis is currently lacking.
Objectives
To compare mid-term device-associated outcomes in a large real-world cohort of S-ICD patients, stratified by age at implantation.
Methods
Two propensity-matched cohorts of teenagers + young adults (≤ 30-year-old) and adults (> 30-year-old) were retrieved from the ELISIR registry. The primary outcome was the comparison of the inappropriate shock rate; complications, freedom from sustained ventricular arrhythmias, overall and cardiovascular mortality were deemed secondary outcomes.
Results
Teenagers + young adults represented 11.0% of the entire cohort. Two propensity-matched groups of 161 patients each were used for the analysis; median follow-up was 23.1 [13.2-40.5] months. 15.2% patients experienced inappropriate shocks and 9.3% device related complications were observed, with no age-related differences in inappropriate shocks (16.1% vs 14.3%; p=0.642) and complication rates (9.9% vs 8.7%; p=0.701). At univariate analysis, young age was not associated with increased rates of inappropriate shocks (HR 1.204 [0.675-2.148]: p=0.529). At multivariate analysis, the use of SMART pass algorithm was associated to a strong reduction in inappropriate shocks (aHR 0.292 [0.161-0.525]; p<0.001), while ARVC was associated with higher rates of inappropriate shocks (aHR 2.380 [1.205-4.697]; p=0.012).
Conclusion
In a large multicentered registry of propensity-matched patients, the use of S-ICD in teenagers/young adults resulted safe and effective. The rates of inappropriate shocks and complications between cohorts were not significantly different. The only predictor of increased inappropriate shocks was a diagnosis of ARVC.

Copyright © 2022. Published by Elsevier Inc.

Heart Rhythm: 03 Mar 2022; epub ahead of print
Gulletta S, Gasperetti A, Schiavone M, Vogler J, ... Forleo GB, Tilz R
Heart Rhythm: 03 Mar 2022; epub ahead of print | PMID: 35257974
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Markers of NET formation and stroke risk in patients with atrial fibrillation: association with a prothrombotic state.

Mołek P, Ząbczyk M, Malinowski KP, Natorska J, Undas A
Introduction
Neutrophil extracellular traps (NETs) formation contributes to thrombosis but its role in atrial fibrillation (AF) is poorly explored. We investigated whether increased circulating NETs markers in relation to a hypercoagulable state can predispose to ischemic stroke in anticoagulated AF patients during long-term follow-up.
Materials and methods
In this cohort study 243 AF patients (median age 69 years) were assessed. Serum levels of citrullinated histone H3 (H3cit), myeloperoxidase (MPO), and peptidylarginine deiminase 4 (PAD4), along with plasma fibrin clot permeability (Ks), clot lysis time (CLT), endogenous thrombin potential (ETP), von Willebrand factor (VWF), and fibrinolysis proteins were measured. Stroke/transient ischemic attacks (TIA), major bleeding, and mortality were recorded during a median follow-up of 53 months while on anticoagulation.
Results
Ischemic cerebrovascular events were observed in 20 patients (1.9%/year) who had at baseline higher H3cit, MPO, and PAD4 levels, all positively associated with CLT. Increased thrombin generation correlated positively with H3cit and PAD4, while Ks was inversely associated with H3cit levels. The independent predictors of ischemic stroke/TIA were H3cit (hazard ratio [HR] 9.48, 95% confidence interval [CI] 3.88-22.41, p < 0.0001) and VWF (HR 1.20, 95% CI 1.11-1.49, p = 0.001). Major bleeding (2.0%/year) and all-cause mortality (1.9%/year) were not related to NETs markers.
Conclusions
Enhanced NETs formation related to prothrombotic markers is associated with increased risk of stroke/TIA in AF patients, suggesting a prognostic value of NETosis in AF.

Copyright © 2022 Elsevier Ltd. All rights reserved.

Thromb Res: 03 Mar 2022; 213:1-7
Mołek P, Ząbczyk M, Malinowski KP, Natorska J, Undas A
Thromb Res: 03 Mar 2022; 213:1-7 | PMID: 35276507
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Tricuspid and mitral remodelling in atrial fibrillation: a three-dimensional echocardiographic study.

Ortiz-Leon XA, Posada-Martinez EL, Trejo-Paredes MC, Ivey-Miranda JB, ... Arias-Godinez JA, Sugeng L
Aims
Atrial fibrillation (AF) is associated with atrial enlargement, mitral annulus (MA) and tricuspid annulus (TA) dilation, and atrial functional regurgitation (AFR). However, less is known about the impact of AF on both atrioventricular valves in those with normal and abnormal ventricular function. We aimed to compare the remodelling of the TA and MA in patients with non-valvular AF without significant AFR.
Methods and results
Ninety-two patients referred for transoesophageal echocardiography were included and categorized into three groups: (i) AF with normal left ventricular (LV) function (Normal LV-AF), n = 36; (ii) AF with LV systolic dysfunction (LVSD-AF), n = 29; and (iii) Controls in sinus rhythm, n = 27. Three-dimensional MA and TA geometry were analysed using automated software. In patients with AF regardless of LV function, the MA and TA areas were larger compared with controls (LVSD-AF vs. Normal LV-AF vs. Controls, end-systolic MA: 5.2 ± 1.1 vs. 4.5 ± 0.7 vs. 3.9 ± 0.7 cm2/m2; end-systolic TA: 5.6 ± 1.3 vs. 5.3 ± 1.3 vs. 4.1 ± 0.7 cm2/m2; P < 0.05 for each comparison with Controls). TA and MA areas were not statistically different between the two AF groups. The TA increase over controls was greater than that of the MA in the Normal LV-AF group (27.7% vs. 15.6%, P = 0.041). Conversely, in the LVSD-AF group, MA and TA increased similarly (35.9% vs. 32.4%, P = 0.660).
Conclusion
Patients with AF showed dilation of both TA and MA compared with patients in sinus rhythm. In patients with normal LV function, AF was associated with greater TA dilation than MA dilation whereas in patients with LVSD the TA and MA were equally dilated.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2022. For permissions, please email: journals.permissions@oup.com.

Eur Heart J Cardiovasc Imaging: 02 Mar 2022; epub ahead of print
Ortiz-Leon XA, Posada-Martinez EL, Trejo-Paredes MC, Ivey-Miranda JB, ... Arias-Godinez JA, Sugeng L
Eur Heart J Cardiovasc Imaging: 02 Mar 2022; epub ahead of print | PMID: 35243501
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Electrophysiology and Arrhythmogenesis in the Human Right Ventricular Outflow Tract.

Aras K, Gams A, Faye R, Brennan J, ... Bernus O, Efimov IR
Background
Right ventricular outflow tract (RVOT) is a common source of ventricular tachycardia, which often requires ablation. However, the mechanisms underlying the RVOT\'s unique arrhythmia susceptibility remain poorly understood due to lack of detailed electrophysiological and molecular studies of the human RVOT.
Methods
We conducted optical mapping studies in 16 nondiseased donor human RVOT preparations subjected to pharmacologically induced adrenergic and cholinergic stimulation to evaluate susceptibility to arrhythmias and characterize arrhythmia dynamics.
Results
We found that under control conditions, RVOT has shorter action potential duration at 80% repolarization relative to the right ventricular apical region. Treatment with isoproterenol (100 nM) shortened action potential duration at 80% repolarization and increased incidence of premature ventricular contractions (P=0.003), whereas acetylcholine (100 μM) stimulation alone had no effect on action potential duration at 80% repolarization or premature ventricular contractions. However, acetylcholine treatment after isoproterenol stimulation reduced the incidence of premature ventricular contractions (P=0.034) and partially reversed action potential duration at 80% repolarization shortening (P=0.029). Immunolabeling of RVOT (n=4) confirmed the presence of cholinergic marker VAChT (vesicular acetylcholine transporter) in the region. Rapid pacing revealed RVOT susceptibility to both concordant and discordant alternans. Investigation into transmural arrhythmia dynamics showed that arrhythmia wave fronts and phase singularities (rotors) were relatively more organized in the endocardium than in the epicardium (P=0.006). Moreover, there was a weak but positive spatiotemporal autocorrelation between epicardial and endocardial arrhythmic wave fronts and rotors. Transcriptome analysis (n=10 hearts) suggests a trend that MAPK (mitogen-activated protein kinase) signaling, calcium signaling, and cGMP-PKG (protein kinase G) signaling are among the pathways that may be enriched in the male RVOT, whereas pathways of neurodegeneration may be enriched in the female RVOT.
Conclusions
Human RVOT electrophysiology is characterized by shorter action potential duration relative to the right ventricular apical region. Cholinergic right ventricular stimulation attenuates the arrhythmogenic effects of adrenergic stimulation, including increase in frequency of premature ventricular contractions and shortening of wavelength. Right ventricular arrhythmia is characterized by positive spatial-temporal autocorrelation between epicardial-endocardial arrhythmic wave fronts and rotors that are relatively more organized in the endocardium.



Circ Arrhythm Electrophysiol: 02 Mar 2022:CIRCEP121010630; epub ahead of print
Aras K, Gams A, Faye R, Brennan J, ... Bernus O, Efimov IR
Circ Arrhythm Electrophysiol: 02 Mar 2022:CIRCEP121010630; epub ahead of print | PMID: 35238622
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

The Role of Preoperative Venography in Predicting the Difficulty of a Transvenous Lead Extraction Procedure.

Aboelhassan M, Bontempi L, Cerini M, Salghetti F, ... Dell\'Aquila A, Curnis A
Introduction
We hypothesized that an accurate assessment of preoperative venography could be useful in predicting transvenous lead extraction (TLE) difficulty.
Methods and results
A dedicated preoperative venogram was performed in consecutive patients with cardiac implantable electronic device who underwent TLE. The level of stenosis was classified as without significant stenosis, moderate, severe, and occlusion. The presence of extensive lead-venous wall adherence (≥50 mm) was also assessed. A total of 105 patients (median age 71 years; 72% male) with a median of 2(1-2) leads to extract were enrolled. Preoperative venography showed moderate to severe stenosis in 31(30%), complete occlusion in 15(14%), and extensive lead-venous wall adherence in 50 (48%) patients. Complete TLE success was achieved in 103(98%) patients. Fifty-five (52%) were advanced extractions as they required a power mechanical and/or laser sheath. They were more prevalent in the group with extensive lead-venous wall adherence (72% vs. 34%, p<0.001), while no differences were found between patients with and without venous occlusion. In multivariate analysis, the presence of adherence was a predictor of advanced extraction (odds ratio 2.89[1.14-7.32], p=0.025). The fluoroscopy time was also significantly longer (14.0[8.2-18.7] vs. 5.1[2.1-10.0] min, p<0.001). The rate of complications did not differ based on the presence of venous lesions.
Conclusion
Although procedural success and complication rates were similar, patients with extensive lead-venous wall adherence required a longer fluoroscopy time and were 3 times more likely to need advanced extraction tools. Conversely, the presence of total venous occlusion had no impact on the procedure complexity. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.

J Cardiovasc Electrophysiol: 02 Mar 2022; epub ahead of print
Aboelhassan M, Bontempi L, Cerini M, Salghetti F, ... Dell'Aquila A, Curnis A
J Cardiovasc Electrophysiol: 02 Mar 2022; epub ahead of print | PMID: 35243712
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Abstract

Remote Programming of Cardiac Implantable Electronic Devices: A Novel Approach to Program Cardiac Devices for Magnetic Resonance Imaging.

Siddamsetti S, Shinn A, Gautam S
Background
Magnetic Resonance imaging (MRI) in patients with MRI-conditional cardiovascular implantable electronic devices (CIED) remain a logistical issue for device programming during the scan. In current practice, a trained person needs to be present on-site to program CIED for MRI scan. This can cause delay in patient care, rescheduling of tests and increase healthcare costs. A novel remote programming (RP) strategy can be utilized to reprogram the CIED remotely. We sought to explore the feasibility and safety of RP of CIEDs in patients undergoing MRI scan.
Methods
We implemented the Medtronic CIED RP software at our institution after ensuring HIPAA compliance. The MRI technician started the session by contacting an off-site remote operator and placing a programmer wand from the 2090 Medtronic programmer over the CIED. The remote operator logged into a remote access software and provided a unique access code to the MRI technician. After entering the access code into the programmer, the remote operator was able to program the device as needed. We conducted a periodic audit of the first 209 patients who underwent RP of CIEDs for MRI. Outcomes analyzed were successful completion of RP sessions and time saved per scan.
Results
Of the 209 MRI scans, 51 scans were performed urgently. There were no connectivity and programming problems or need for MRI rescheduling. In-person reprogramming was not required for any patient. All scans were completed safely in a timely manner, and there were no reports of CIED malfunction. Time saved per scan was estimated to be 28 +/-10 minutes.
Conclusions
Remote programming of CIEDs for MRI scans is a safe and effective strategy. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.

J Cardiovasc Electrophysiol: 02 Mar 2022; epub ahead of print
Siddamsetti S, Shinn A, Gautam S
J Cardiovasc Electrophysiol: 02 Mar 2022; epub ahead of print | PMID: 35243710
Go to: DOI | PubMed | PDF | Google Scholar |
Impact:
Older ...

This program is still in alpha version.